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Elisabeth A. Lasater 
DISSECTING NEUROFIBROMATOSIS TYPE 1 RELATED VASCULOPATHY 
Neurofibromatosis type 1 (NF1) is a genetic disorder resulting from 
mutations in the tumor suppressor gene NF1.  NF1 encodes the protein 
neurofibromin, which functions to negatively regulate p21Ras signaling.  NF1 has 
a wide range of clinical manifestations, including vascular disease, which is 
characterized by neointima formation and subsequent vessel occlusion.  Despite 
numerous clinical observations of NF1 vasculopathy, the pathogenesis of 
vascular lesion formation remains unclear.  To determine the consequence of 
Nf1 haploinsufficiency in vascular disease, we generated an in vivo model for 
dissecting vascular lesion formation.  In response to mechanical arterial injury, 
Nf1+/- mice have significantly enhanced neointima formation characterized by an 
accumulation of vascular smooth muscle cells (VSMCs) and excessive cellular 
proliferation and Ras activation.  Further, using the pharmacological antagonist, 
imatinib mesylate, we identified that neointima formation in Nf1+/- mice was 
directly dependent on Ras signaling through either the platelet derived growth 
factor β receptor (PDGF-βR) and/or the C-kit receptor activation.  These 
observations identify a molecular mechanism of neointima formation given that 
our group has previously demonstrated that Nf1+/- VSMCs have hyperactive Ras 
signaling through PDGF-βR activation and Nf1+/- bone marrow derived cells 
(BMDCs) have increased recruitment and survival in response to C-kit activation 
compared to WT controls.  In order to dissect the cellular contribution to 
vi 
 
neointima formation, we utilized cre/lox technology and adoptive hematopoietic 
stem cell transfer techniques to genetically delete one allele of Nf1 in endothelial 
cells, VSMCs or BMDCs individually to test which cell lineage is predominant in 
NF1 vasculopathy.  Surprisingly, in response to carotid artery injury, 
heterozygous inactivation of Nf1 in BMDCs alone was necessary and sufficient 
for neointima formation.  Specifically, Nf1 haploinsufficiency in BMDCs resulted 
in an infiltration of macrophages into the neointima, providing evidence of 
“vascular inflammation” as factor in NF1 vasculopathy.  Further, we demonstrate 
for the first time that NF1 patients have evidence of chronic inflammation 
determined by increased concentrations of circulating monocytes and pro-
inflammatory cytokines.  In sum, we provide genetic and cellular evidence of 
vascular inflammation in NF1 patients and Nf1+/- mice and provide a framework 
for understanding the pathogenesis of NF1 vasculopathy and potential 
therapeutic and diagnostic interventions. 
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Neurofibromatosis Type 1. 
Neurofibromatosis type 1 (NF1) is an autosomal dominate disorder that 
affects 1 in 3500 individuals (1).  NF1 results from mutations in the tumor 
suppressor gene NF1, which encodes the protein product neurofibromin (2).  The 
NF1 gene, originally described in 1990 (3-5), spans 350 kilobases of DNA on 
chromosome 17 and contains 60 exons (6).  Although NF1 is generally 
considered a familial disorder, approximately fifty-percent of patients do not have 
an affected parent.  Consistent with this finding, the NF1 gene has been 
described as having one of the highest mutation rates in humans (7, 8), with over 
240 different  mutations described throughout the gene (9).  Mutations described 
to date include insertions, duplications, substitutions, nonsense mutations, 
frameshift mutations, and gene deletions (10), resulting in little or no protein 
product.  The germline mutations that cause NF1 affect only one allele of the 
NF1 gene (11), however, loss of heterozygosity has been described in from 
primary tumor samples taken from NF1 patients, indicating the role of NF1 as a 
tumor suppressor gene (12). 
NF1 is a complete penetrance genetic disorder and manifestation of the 
disease varies greatly among patients as well as with age.  Clinical diagnosis of 
NF1 is confirmed if a patient meets two or more of the criteria established by the 
National Institutes of Health (NIH) (13) which is defined as: 1) the presence of six 
or more café-au-lait macules over 5 millimeters (mm) in diameter for prepubertal 
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individuals or 15mm in greatest diameter for postpubertal individuals, 2) two or 
more neurofibromas or one plexiform neurofibroma, 3) axillary or inguinal 
freckling, 4) optic glioma, 5) two or more Lisch nodules, 6) distinctive osseous 
abnormality, or 7) a first degree relative diagnosed with NF1 by the NIH criteria 
(13).  Additional manifestations of NF1 which complicate clinical management 
include learning disabilities, malignant peripheral nerve sheath tumors, myeloid 
leukemias, and vascular lesions.  
 
NF1 and Vascular Disease.   
One of the least studied complications of NF1 involves disorders of the 
cardiovascular system.  Although the exact frequency of vascular lesions is 
unknown, vasculopathy is an under-recognized complication of the disease and 
contributes to excess morbidity and mortality particularly among younger patients 
(14-17).  NF1 vasculopathy was first described in 1945 (18) and was further 
classified in 1974 based on the size of the lesion and the vessel effected (19).  
Specifically, NF1 patients develop aneurysms, stenosis and arterial occlusions 
that result in cerebral and visceral infarcts (14-17, 20).  NF1 vascular lesions are 
characterized by an accumulation of vascular smooth muscle cells (VSMCs) in 
the intima area of the vessel (termed neointima formation) resulting in lumen 
occlusion (14, 21, 22). 
 In 2001, an analysis of 3,253 death certificates of persons with NF1 
indicated that the median age of death for NF1 patients was fifteen years less 
that of the general population (16).  In this report, a diagnosis suggestive of NF1 
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vasculopathy was listed 7.2 times more often than expected among NF1 patients 
less than 30 years old at time of death and 2.2 times more often than expected 
among patients 30 to 40 years old at the time of death (16).  Another study 
demonstrated that 2.5% of children with NF1 who had undergone brain MRI were 
found to have cerebrovascular system abnormalities including narrowed vessels, 
moya-moya, vascular stenosis and aneurysm (17).  Although rare, sudden death 
in individuals with NF1 has been reported in both adults and children and 
vascular lesions have been identified in these patients.  Most recently, a 22-
month old male was found to have 33% luminal reduction in the left main 
coronary artery and left anterior descending coronary artery at the time of death 
(22).  In an unrelated patient, an adolescent male had 90% luminal occlusion of 
the left main coronary artery and left anterior descending coronary artery at the 
time of death (22).  Vascular lesions described in both patients were consistent 
with NF1 vasculopathy with histopathology including intimal hyperplasia and 
VSMC proliferation (21).  Despite numerous clinical observations, the molecular 
mechanism that underlies the cardiovascular complications of NF1 is virtually 
unknown.  In 2002, the NF1 Cardiovascular Task Force made research 
recommendations with included the development of a valid experimental model 
of NF1 vasculopathy in a laboratory animal or an in vitro system to dissect the 
molecular basis of NF1-associated cardiovascular disease in order to improve 
care for patients (14).  Therefore, studies outlined in this project developed an 
expandable in vivo murine model of NF1 vasculopathy to test the hypothesis that: 
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1.  Nf1+/- mice have increased neointima formation in response to 
vascular injury compared to wildtype (WT) controls. 
2. Heterozygous inactivation of Nf1 in VSMCs directly leads to increased 
neointima formation in response to vascular injury compared to WT 
controls. 
3. Increased neointima formation in Nf1+/- mice compared to WT controls 
is a result of hyperactive signaling through the PDGF-receptor. 
   
Neurofibromin.   
Neurofibromin, the product encoded by NF1, is a 2818 amino acid protein 
(23) that contains 60 exons (6).  Neurofibromin is expressed in all cell lineages 
analyzed to date, including neurons, glial cells, Schwann cells, leukocytes, 
astrocytes, vascular smooth muscle cells (VSMCs), endothelial cells (ECs) and 
fibroblasts (24-28).  In vivo studies have demonstrated that at least some 
neurofibromin expression is required for normal development in mice.  Germline 
homozygous deletion of Nf1 is embryonic lethal around day 13.5 and dissection 
of Nf1-/- mutants determined that embryonic lethality was due to cardiac 
malformation (29, 30).  Specifically, the absence of neurofibromin during 
development results in a condition in which the pulmonary artery and aorta both 
emerge from the right ventricle.  However, Nf1+/- embryos are viable and 
development normally with no sign of cardiac malformation.  Adult Nf1+/- mice do 
not develop neurofibromas, café-au-lait macules or Lisch nodules and therefore 
are phenotypically the same to WT mice.  However, in prolonged studies over a 
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period of 27 months, Nf1+/- mice did show a predisposition to tumor formation as 
well as myeloid leukemia (30).  These observations, along with genetic studies 
that indicate NF1 is caused from mutations within a single allele provide evidence 
that NF1 is a tumor suppressor gene (31).  While, loss of heterozygosity has 
been described in some tumors isolated from NF1 patients (32-34), 
haploinsufficiency of NF1 is sufficient for many of the clinical manifestations of 
NF1 (35-39).  
The most extensively studied role of neurofibromin, to date, is its function 
regulating p21Ras (Ras) signaling.  Neurofibromin has been demonstrated to have 
a catalytic domain with sequence homology to the mammalian Ras guanosine 
triphosphate accelerating protein (GAP), p120 Ras-GAP, and the yeast Ras 
inhibitors IRA1 and IRA2 (2, 40-42).  The activity of Ras proteins is tightly 
controlled by cycling between an activated guanosine triphosphate bound state 
(Ras-GTP) and an inactivated guanosine diphosphate bound state (Ras-
GDP)(43-45).  GAP proteins, including neurofibromin, accelerate the hydrolysis 
of GTP to GDP, converting active Ras-GTP to inactivate Ras-GDP (Figure 1) and 
negatively regulating Ras signaling (2, 44, 46).  The GAP domain of 
neurofibromin spans exons 20 through 27 and introduction of only this GAP 
related domain (GRD) is sufficient to stimulate GTP hydrolysis of Ras in yeast (2, 
40, 42).  Further experiments have also shown that the GRD domain of 
neurofibromin functions as effectively as a Ras-GAP as the full length protein 
(47).  Consistent with its function, primary cells isolated from both NF1 patients 
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and Nf1+/- mice have hyperactivated Ras signaling pathways, including ECs and 


































 While neurofibromin functioning as a Ras-GAP can be attributed to many 
of the in vitro and in vivo observations described in NF1, the GAP domain only 
accounts for 10% of the NF1 gene (50), indicating additional roles of 
neurofibromin in cellular function.  Studies in Drosophila have demonstrated that 
neurofibromin positively regulates adenylyl cyclase (51-53) (Figure 2) and 
mutations within NF1 result in reduced cyclic adenosine 3’,5’-monophosphate 
(cAMP) production and downregulation of protein kinase A (PKA) signaling (51, 
52).  Homozygous NF1 mutant Drosophila present with small size and decreased 
lifespan (51, 53) that was not recapitulated by upregulation of the Ras-Raf 
signaling axis.  However, these studies identified that mutation of adenylyl 
cyclase, the enzyme which produces cAMP from adenosisne triphosphate (ATP), 
also results in small size and decreased lifespan (53).  Further, the NF1 null 
phenotype is corrected by mutation of cAMP phosphodiesterase, which inhibits 
cAMP degradation, as well as constitutive activation of PKA (53).  Along with 
identifying the signaling axis, Tong et al. (53) demonstrated that loss of 
neurofibromin resulted in increased mitochondrial oxidative stress.  These 
studies suggest that neurofibromin is a regulator of adenylyl cyclase-cAMP-PKA 
signaling.  These observations in Drosophila have encouraged the interrogation 
of neurofibromin-adenylyl cyclase signaling in mammalian cells.  Dasgupta et al. 
(54) have identified that neurofibromin positively regulates adenylyl cyclase 
activity in astrocytes regulating cellular proliferation.  Interestingly, Kim et al. (55) 
have demonstrated that neurofibromin negatively regulates cAMP production in 
Schwann cells.  These conflicting observations reveal that the function of 
9 
 
neurofibromin in regulating cAMP production is dependent on cell lineage and 
additional studies need to be completed to determine the role of neurofibromin 
and cAMP in NF1 manifestations.  To this point, in vitro studies in Dr. Ingram’s 
lab have demonstrated the ECs transduced with short hairpin RNA (shRNA) 
directed against NF1 have reduced levels of cAMP compared to control ECs 
(Figure 3).  The cellular consequence of reduced cAMP levels in neurofibromin 
deficient ECs needs to be further investigated to determine if this signaling axis is 




















Figure 2.  Simplified schematic of positive regulation of adenylyl cyclase 




























Figure 3.  Quantitative analysis of cAMP levels in control and 
neurofibromin deficient ECs.  Cytoplasmic cAMP levels in ECs transduced with 
either scrambled shRNA (Control shRNA) or shRNA targeted against NF1 (NF1 
shRNA) in pg/mol per 106 cells.  Data represents the mean cAMP levels ± SEM, 





















Vascular Smooth Muscle Cells, Ras Activation and Neointima Formation.   
Arteries are composed of three primary regions, the intima, media and 
adventitia.  The intima area is the innermost region of the artery and consists of a 
monolayer of ECs resting on a basement membrane within the internal elastic 
lamina.  The ECs function as a barrier between the blood and VSMCs within the 
vessel wall regulating the transmigration of cells into the vessel (56, 57).  Further, 
ECs produce nitric oxide, which is important for regulating vascular tone and a 
potent inhibitor of VSMC proliferation (58).  The media area of the vessel, the 
interior region between the internal elastic lamina and external elastic lamina, is 
composed primarily of quiescent VSMCs and extracellular matrix.  The adventitia 
is the outermost region of the vessel and is composed of fibroblasts and 
connective tissue (Figure 4).  Vascular homeostasis requires a controlled 
interaction between the three regions to inhibit the infiltration cells into the vessel 
wall from either the lumen or adventitia, as well as maintain the VSMCs within 























Figure 4.  Schematic of an arterial cross-section and neointima formation.               
A)  Cross-section of a normal murine carotid artery that has been stained with 
Hematoxylin/Eosin (H&E) to identify nuclei (blue) and cellular cytoplasm (pink).  
Black box identifies area magnified in the right panel.  B)  Cross-section of 




















Vascular occlusive disease is characterized by an accumulation of VSMCs 
within the intima area of the vessel (neointima formation), which results in lumen 
occlusion.  Studies by others have demonstrated that in response to injury, 
VSMCs from the media migrate into the intima in response to platelet derived 
growth factor BB (PDGF-BB) where they proliferate and produce extracellular 
matrix, forming the neointima (59-61).  Arterial injury results, initially, in the 
accumulation of platelets at the sites of exposed collagen due to loss of the 
endothelium.  Platelets are a potent source of PDGF-BB which serves as a 
necessary stimulant for medial VSMCs to migrate into the intima area in 
response to injury (61, 62).  Further, the importance of PDGF-BB signaling 
through the PDGFβ-receptor (PDGFβ-R) has been elucidated in a number of in 
vivo models where mice harboring genetic mutations that increase signaling 
through the PDGFβ-R-Ras-Erk signaling axis develop exaggerated neointimal 
hyperplasia and arterial occlusive disease reminiscent of the vascular 
complications which develop in some NF1 patients (63-72). 
Ras proteins regulate the growth, survival and differentiation of many cell 
types by functioning as a molecular switch that relays signals from the 
extracellular environment to the nucleus (45, 73-76).  Therefore, based on the 
global control of Ras signaling in regulating cell function, deficiency of 
neurofibromin in VSMCs could contribute to neointima formation.  Neurofibromin 
is expressed in human and murine VSMCs and has been demonstrated to 
function as a Ras GAP, negatively regulating Ras signaling (28, 48).  In vitro data 
from our laboratory demonstrated that neurofibromin deficient human and murine 
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VSMCs have increased proliferation and migration in response to PDGF-BB and 
that the hyperactivation is abrogated by pre-incubation of the cells with either the 
Mek inhibitor PD98059 or imatinib mesylate (48).  Further, stimulation of Nf1+/- 
VSMCs demonstrated increased Erk phosphorylation in response to PDGF-BB 
stimulation compared to WT VSMCs with no difference detected in Akt 
phosphorylation between Nf1+/- and WT VSMCs (48).  This data identifies the 
canonical Ras-Raf-Mek-Erk (Ras-Erk) signaling pathway as the primary axis for 
the increased proliferation and migration of the Nf1+/- VSMCs, therefore studies 
outlined in this project will focus on Ras-Erk signaling in vivo.  Understanding the 
role of neurofibromin in VSMCs gives potential insights into NF1 vasculopathy 
given the emerging paradigm in vascular biology where tight control of the 
PDGF-BB-Ras-Erk signaling axis in VSMCs is critical for maintaining in blood 
vessel homeostasis and preventing premature development of vascular occlusive 
disease (68-72, 77, 78). 
Traditionally, the role of Ras signaling in neointima formation has centered 
on activating Ras mutations or mutation of proteins within the Ras signaling 
scaffold.  For example, Grb2 is a critical adapter molecule required for the 
activation of Ras by receptor tyrosine kinases, including the PDGFR-βR (72).  
Grb2+/- mice are resistant to neointima formation in response to mechanical 
arterial injury compared to WT controls (72).  Consistent with this result, in vitro 
studies indicate that murine Grb2+/- VSMCs have decreased proliferation and 
migration in response to PDGF-BB compared to WT controls (72).  Similar 
results were obtained through the use of a pharmacological inhibitor of Mek in 
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rats (79), as well as the adenoviral mediated transfer of a dominant negative H-
Ras into VSMCs (68), both of which prevent the development of stenotic lesions 
after mechanical arterial injury by inhibiting the proliferation and migration of 
VSMCs.  In 2004, Chen et al. (65) demonstrated that the loss of a negative 
regulator of Ras activity resulted in neointima formation in response to vascular 
injury.  The protein product of hyperplasia suppressor gene (HSG) directly binds 
to Ras, inhibiting the activation of the Ras-Erk signaling axis and inducing cell 
cycle arrest (65).  HSG protein and mRNA expression is dramatically reduced in 
hyperproliferative VSMCs in vitro as well as in response to mechanical arterial 
injury.  This finding supports the hypothesis that increased Ras-Erk signaling in 
VSMCs through the loss of a negative regulator is sufficient to drive neointima 
formation in response to injury.  Based on these observations, we hypothesize 
that Nf1+/- VSMCs would have increased migration in response to arterial injury, 
resulting in enhanced neointima formation.    
 
Endothelial Cells, Ras Activation and Neointima Formation.   
Neurofibromin has a critical role in regulating EC function.  Complete 
germline inactivation of Nf1 results in midgestation lethality due to cardiovascular 
malformations (29, 30).  Lineage specific inactivation has shown that expression 
of Nf1 in ECs is essential for normal embryonic development (80).  Utilizing 
transgenic mice that express conditional Nf1 alleles that are susceptible to cre 
mediated recombination, Gitler et al. demonstrated that complete ablation of Nf1 
in ECs driven by the EC promoter, Tie2, recapitulates the phenotype of the Nf1-/- 
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embryo (80).  These results indicate that neurofibromin plays a critical role in 
normal cardiovascular development and therefore we hypothesize that 
neurofibromin also has an important role in maintaining vessel homeostasis. 
ECs derived from NF1 patients have reduced neurofibromin expression 
consistent with heterozygous inactivation of NF1 (49).  Decreased neurofibromin 
expression results in increased Ras activation in vitro, determined by increased 
Erk phosphorylation, in response to vascular endothelial growth factor (VEGF) 
and basic fibroblast growth factor (bFGF).  Further, we have shown that primary 
human ECs derived from NF1 patients have increased proliferation and migration 
in response to VEGF and bFGF through hyperactivation of the Ras-Erk signaling 
axis (49).  The effects of prolonged activation of Ras in ECs in NF1 patients are 
unknown; although oncogenic Ras signaling in ECs has been linked to cellular 
senescence in vitro (81).  This observation is intriguing given that EC 
senescence has been associated with vascular disease in other patient 
populations (58, 82).   
Cellular senescence is an irreversible growth arrest that is generally 
attributed to telomere shortening and chromosome instability (83).  This form of 
senescence, termed replicative senescence, limits the proliferative potential of a 
cell (84-86).  Another form of senescence, termed stress-induced or premature 
senescence, is independent of telomere shortening and can be induced by a 
number of challenges, including DNA damage, oxidative stress or oncogenic 
transformation (58, 87).  The functional consequences of EC senescence, either 
replicative or premature, include decreased production of nitric oxide, decreased 
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repair ability in response to injury and increased expression of cellular adhesion 
molecules which could predispose patients to vascular lesion formation (58).    
The endothelium forms a continuous monolayer that lines the lumen side 
of the vasculature and is essential for maintaining the integrity of the vessel wall.  
Normal functioning ECs produce nitric oxide, a multi-functional compound which 
regulates vascular tone, inhibits VSMC proliferation, and has anti-inflammatory 
effects (58).  Endothelial nitric oxide synthase (eNOS), a constitutively expressed 
EC enzyme, produces nitric oxide through the conversion of L-arginine to L-
citrulline.  A hallmark of senescence and subsequent endothelial dysfunction is 
reduced nitric oxide production, which has been associated in vitro with 
decreased eNOS activity (88, 89).  Reduction in eNOS activity has been 
attributed to reduced telomerase activity (88), oxidative stress (90, 91) and 
changes in shear stress (92).  Endothelial dysfunction mediated by changes in 
shear stress or increased oxidative stress implicates the role of premature 
senescence in vascular disease (58, 93, 94) because the anti-inflammatory 
effects of nitric oxide function to inhibit platelet aggregation and adherence to 
ECs (95-97) as well as regulate the expression of leukocyte adhesion molecules, 
such as intracellular adhesion molecule 1 (ICAM-1) in vitro (98).  This is an 
interesting observation given that recruitment of circulating inflammatory cells to 
the vessel wall can result in increased oxidative stress and EC activation, 
perpetuating an inflammatory response.          
EC activation by inflammatory mediators has been linked to vascular 
disease in patient populations with lesions reminiscent of NF1 vasculopathy.  
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Increased serum levels of the pro-inflammatory cytokines tumor necrosis factor α 
(TNFα) and interleukin 6 (IL-6) have been associated with atherosclerosis and 
coronary artery disease (99-103).  Endothelial activation by inflammatory 
mediators upregulates the expression of leukocyte adhesion molecules, including 
ICAM-1 and vascular cell adhesion molecule 1 (VCAM-1) as well as the 
chemokine monocyte chemoattractant protein 1 (MCP-1) (104).  These leukocyte 
adhesion molecules and chemokines mediate the recruitment and binding of 
leukocytes to the endothelium, facilitating the transmigration of cells into the 
vessel wall (105).  The infiltration of monocytes/macrophages, natural killer (NK) 
cells, dendritic cells, T cells, B cells and mast cells have all been described in 
vascular lesion formation (106, 107).  In vivo models utilizing antibody blockade 
of adhesion molecules or genetic ablation of leukocyte receptors have 
determined that transmigration of inflammatory cells into the vessel wall is 
essential for neointima formation in response to arterial injury (108-111).  These 
observations provide a potential mechanism through which EC senescence 
results in a recruitment of circulating inflammatory cells to the vessel wall, 
initiating vascular lesion formation.                
Recent unpublished studies from Dr. Ingram’s laboratory show that ECs 
isolated from NF1 patients’ peripheral blood and expanded ex vivo undergo 
premature senescence compared to healthy donors (Figure 5).  Specifically, 
these primary cells have increased population doubling time (Figure 5b) and 
show reduced growth kinetics compared to ECs derived from healthy adult 
controls (Figure 6).  However, targeted reduction of neurofibromin in ECs by 
22 
 
shRNA does not result in premature senescence or reduced growth kinetics 
compared to controls (Figure 6), indicating that premature senescence detected 
in primary NF1 ECs is not cultural artifact and is potentially a result of increased 
stress in vivo.  Preliminary studies utilizing ECs derived from NF1 patients and 
age-matched healthy controls showed that NF1 ECs have increased oxidative 
DNA damage compared to control ECs, determined by expression of the 
oxidative DNA adduct 8-oxo-deoxyguanosine (Figure 5c).  Inflammatory cells, 
specifically monocytes and macrophages are potent sources of reactive oxygen 
species.  Recruitment of these cells to the vessel wall either through vascular 
injury, changes in shear stress, or endothelial activation by inflammatory 
cytokines could result in stress-induced premature senescence of ECs that line 
the vessel wall in NF1 patients (56, 112, 113).  Therefore, cellular dysfunction as 
a consequence of haploinsufficiency of NF1 would result in transmission of 
migratory and proliferative signals to VSMCs, and/or increased expression of 






















Figure 5.  Identification of premature senescence of peripheral blood 
derived ECs from NF1 patients.  A)  Representative photomicrographs of 
senescence associated beta-galactosidase stain of age and passage matched 
ECs derived from the peripheral blood of healthy adult controls (left panel) or 
NF1 patients (right panel).  Blue staining indicates cellular senescence.  
Photomicrographs are representative of 6 independent observations.  B)  
Quantification of average population doubling time (PDT) of ECs derived from 
healthy controls and NF1 patients.  Data represents average PDT ± SEM, n=6, 
*p=0.031 by Student’s unpaired t test with Welch correction.  C)  Histogram of 8-
oxo-deoxyguanine expression in cultured ECs derived from healthy adult control 


















Figure 6.  Growth kinetics of peripheral blood derived ECs and shRNA 
transduced ECs.  A)  Representative growth kinetics curve of cultured ECs 
derived from sex and age matched healthy adult control (blue line) and NF1 
patient (red line) peripheral blood indicating reduced cumulative population 
doubling level (CPDL) of NF1 patient ECs.  B)  Representative growth kinetics 
curve of human microvascular cells transduced with control shRNA (blue line) or 



















Bone Marrow Derived Cells and Neointima Formation.   
Bone marrow derived cell (BMDCs) are mobilized in response to vascular 
injury and are required for repair and remodeling (114, 115).  Although neointima 
formation after injury has been described as local proliferation of VSMCs, recent 
data demonstrates that bone marrow derived inflammatory cells directly 
contribute to neointima initiation and progression (111, 115-119).  Leukocyte 
transmigration into the vessel wall in response to vascular injury is essential for 
neointima formation.  The requirement for the infiltration of BMDCs in neointima 
formation has been demonstrated through genetic ablation of receptors known to 
facilitate leukocyte transmigration, including Mac-1 (111) and CCR2 (120).  Along 
with the requirement for leukocyte attachment and transmigration into the vessel 
wall in neointima formation, a recent study indicates that neointima formation is 
dependent, at least in part, on activation of the C-kit signaling pathway (115).  
Wang et al demonstrated that C-kit deficient mice have reduced neointima 
formation in response to arterial injury (115).  Further, bone marrow 
transplantation of the C-kit deficient mice with WT bone marrow restored 
neointima formation in response to injury.      
Stem cell factor (SCF) is the ligand for the C-kit receptor and activation of 
C-kit by SCF has been shown to regulate hematopoietic stem cell proliferation, 
survival and recruitment (121-124).  In vivo, circulating levels of SCF were shown 
to be increased in response to vascular injury, peaking at three days post injury 
(115).  Further, SCF deficiency attenuated neointima formation in response to 
injury (115).  This observation is intriguing given that our group provided the first 
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genetic data that Nf1+/- myeloid cells have increased proliferation, survival and 
migration mediated through SCF activation of the C-kit-Ras signaling compared 
to WT controls (125-127).  Along with SCF stimulation, Nf1+/- BMDCs have 
increased Ras activation in response to granulocyte/macrophage colony 
stimulating factor (GM-CSF) (128-130).  As with SCF, GM-CSF has been shown 
to directly influence the accumulation of BMDCs within the neointima in response 
to injury.  GM-CSF stimulation increases the adhesion of monocytes to the 
endothelium (131, 132) and activates macrophages, stimulating pro-inflammatory 
cytokine production (133), which contributes to neointima formation.  In vivo, GM-
CSF-/- mice have reduced macrophage infiltration and PDGF-BB expression 
within the neointima in response to arterial injury compared to controls (134).  
The reduced accumulation of macrophages due to GM-CSF deficiency is 
hypothesized to account for the reduction in neointima size.  Given the role of 
SCF and GM-CSF in neointima formation and the observation that Nf1+/- BMDCs 
are hypersensitive to activation by these factors, we predict that Nf1+/- mice have 
increased contribution of BMDCs to neointima formation.   
The observation that GM-CSF deficiency attenuates neointima formation 
through the reduced infiltration of macrophages identifies a potential bone 
marrow derived lineage that directly contributes to neointima formation.  Along 
with traditional phagocytic properties, macrophages produce a variety of growth 
factors and cytokines that have been implicated in neointima formation, including 
PDGF-BB which stimulates VSMC migration into the intima area of the vessel in 
response to injury (60, 61, 77, 135, 136).  VSMC migration from the media area 
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into the intima area of the vessel is an essential process in neointima formation 
(59-61) and the release of VSMCs from the extracellular matrix of the media is 
required for this migration.  Macrophages are an important source of matrix 
proteases, which degrade extracellular matrix in the vessel wall, releasing the 
VSMCs to migrate in response to chemotactic stimuli.  In vivo, arterial injury 
induces the expression and activity of the matrix metalloproteinases MMP-2 and 
MMP-9 in the vessel wall (137).  Both VMSCs and macrophages produce and 
secrete MMP-2 and MMP-9 (138-140) and inflammatory cytokines have been 
shown to upregulate the activity of these enzymes (140, 141).  Further, Bendeck 
et al. demonstrated that treating rats with an MMP inhibitor significantly reduced 
neointima formation without effecting the proliferation of medial VSMCs in 
response to injury (137).  In a murine model of neointima formation by flow 
cessation, Godin et al. demonstrated that MMP-9 expression is significantly 
upregulated in ligated carotid arteries as early as 24 hours post ligation and 
remains significantly elevated through day seven post injury (142).  The 
expression of MMPs in neurofibromin deficient VSMCs and macrophages has 
not been investigated, however we hypothesize that hyperactivation of Ras 
signaling in these cells results in increased production/secretion of the proteases, 
mediating neointima formation.  Further, we hypothesize that heterozygous 
inactivation of Nf1 in macrophage results in increased production of growth 
factors and inflammatory cytokines.  This increased macrophage activation would 
subsequently produce an environment for vascular inflammation in both Nf1+/- 
mice and NF1 patients.      
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Vascular Inflammation and Cardiovascular Disease 
 Vascular inflammation has been identified in numerous patient populations 
with vascular lesions reminiscent of NF1 vasculopathy.  Vascular homeostasis 
requires a tightly controlled interaction between vascular ECs, VSMCs and 
circulating inflammatory cells.  In response to activation by inflammatory 
cytokines, ECs increase their expression of chemoattractant proteins and cellular 
adhesion molecules, promoting the recruitment and transmigration of monocytes 
into the vessel wall (112, 143-145).  In circulation, the pro-inflammatory 
monocytes identified by CD14 and CD16 cell surface expression (CD14+CD16+) 
are a major source of inflammatory cytokines, including tumor necrosis factor α 
(TNFα), which is known to induce the expression of cellular adhesion molecules 
on the endothelium (146).  In patients with coronary artery disease, Schlitt et al. 
demonstrated that patients had higher levels of CD14+CD16+ monocytes in 
circulation compared to healthy controls and that there was a positive correlation 
between the frequency of CD14+CD16+ monocytes and the severity of disease 
(102).  Further, this report identified a significant increase in circulating TNFα 
levels that was associated with increased severity of coronary artery disease 
(102).  This observed increase in TNFα in relation to the severity of disease is 
consistent with another report that has demonstrated that levels of TNFα 
correlate with the progression of atherosclerosis (103).  Further, TNFα 
expression has been identified in atherosclerotic lesions and sites of vascular 
injury (99, 147-149) while TNFα deficiency in mice protects against neointima 
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formation in response to injury (150).  These observations identify increased 
expression of pro-inflammatory cytokines as mediators of vascular disease.    
Along with the production of pro-inflammatory cytokines, CD14+CD16+ 
monocytes effectively undergo endothelial attachment and transmigration under 
normal flow conditions due to the expression of the fractalkine receptor CX3CR1 
(151, 152).  CD14+CD16+ monocytes express high levels of CX3CR1 compared 
to other monocyte populations and tightly adhere the vessel wall upon binding to 
fractalkine (153, 154).  Fractalkine is a membrane bound chemokine that 
expressed on ECs activated by inflammatory cytokines, including TNFα and IL-
1(143).  Fractalkine and CX3CR1 produce a high-affinity interaction that allows 
for the transmigration of inflammatory monocytes into the vessel wall.  In vivo, 
CX3CR1 deficiency significantly reduces monocyte infiltration into the vessel wall 
and protects against neointima formation in response to injury (155).  To date, 
the role of inflammation in NF1 vasculopathy has not been determined.  
However, observations in other patient populations provide a mechanism for 











MATERIAL AND METHODS 
 
Animals. 
All protocols for this study were approved by the Indiana University 
Laboratory Animal Research Center.  Nf1+/- mice were obtained from Tyler Jacks 
at the Massachusetts Institute of Technology (Cambridge, MA) in a C57BL/6.129 
background and backcrossed for 13 generations into the C57BL/6J strain.  WT 
C57BL/6 mice were obtained from Harlan Laboratories.  C57BL/6 WT and Nf1+/- 
mice were utilized for the mechanical arterial injury studies.  For the carotid 
ligation studies, Nf1flox/flox mice were obtained from Luis Parada (University of 
Texas Southwestern) and back-crossed 13 generations into the 129SvJ strain.  
Rosa26R lacZ reporter (stock #3474 ), GFP (stock #3291), SM22cre (stock 
#4746) and Tie2cre (stock #4128) mice were purchased from Jackson 
Laboratory (Bar Harbor, ME) and maintained on the C57BL/6 strain.  Nf1flox/flox 
mice were crossed with either SM22cre or Tie2cre mice to generate C57BL/6 x 
129SvJ pups.  Nf1flox/+;SM22cre and Nf1flox/+;Tie2cre mice were used for 
experiments.  Nf1+/- and WT controls were generated by crossing Nf1flox/flox 
129SvJ mice with Nf1+/- C57BL/6 mice.  Rosa26R reporter mice were crossed 
with Nf1flox/flox mice to generate Nf1flox/flox;Rosa26R reporter mice that were 
crossed with either SM22cre or Tie2cre mice.  Nf1+/- mice that ubiquitously 
express GFP were generated by crossing GFP mice with Nf1+/- mice.  Only male 




Genotyping of Mice.  
 DNA was extracted from tail clippings by Proteinase K (Roche) digestion 
followed by ethanol extraction.  The Nf1 allele was genotyped by identifying the 
neomycin resistance gene (neo) expression cassette that has been inserted into 
exon 31 of the Nf1 gene (30).  The 3' primer, TTCAATACCTGCCCAAGG, is 
complementary to a 3' region of exon 31 the Nf1 gene.  The 5' primer, 
CACCTTTGTTTGGAATATATGACT, is complimentary to exon 31 of the Nf1 
gene.  The 5' Nf1 primer and 3' Nf1 primer identify the WT allele and produce a 
230 basepair (bp) fragment.  The 5' neo primer, ATTCGCCAATGACAAGAC, 
along with the 3' Nf1 primer identify the mutant allele and produce a 350-bp 
fragment (127).  The polymerase chain reaction (PCR) program for identifying 
the mutant Nf1 allele is: 95° Celsius (C) for 5 minutes, then 34 cycles of 95°C for 
30 seconds, 55°C for 1 minute and 72°C for 1 minute followed by 72°C for 7 
minutes and held at 4°C.   
 Nf1flox/+;SM22cre and Nf1flox/+;Tie2cre mice were genotyped for cre 
expression by the forward primer 5'- CATTTGGGCCAGCTAAACAT-3' and the 
reverse primer 5'- CCCGGCAAAACAGGTAGTTA-3' which yield a 450-bp 
fragment.  The PCR program for identifying cre is: 94°C for 4 minutes, 27 cycles 
of 94°C for 20 seconds, 65°C for 20 seconds and 72°C for 20 seconds followed 
by 72°C for 2 minutes and held at 4°C.  The conditional flox alleles were 
identified by using three primers.  Two primers, from intron 30 of the Nf1 allele 
yield a 480-bp fragment identifying a WT allele.  The sequence of primer 1 is 5'-
CTTCAGACTGATTGTTGTACCTGA-3' and the sequence of primer two is 5'-
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ACCTCTCTAGCCTCAGGAATGA-3'.  The third primer, 5'-TGATT 
CCCACTTTGTGGTTCTAAG-3' along with primer one yields a 350-bp fragment.  
The PCR program for identifying the conditional Nf1 allele is: 94°C for 3 minutes, 
35 cycles of 94°C for 1 minute, 55°C for 2 minutes and 72°C for 3 minutes 
followed by 72°C for 4 minutes and held at 4°C.  This reaction for the Nf1flox/+ 
mouse yields two fragments, one at 480-bp and the other at 350-bp.   
 Expression of the Rosa26R allele was identified by the combination of 
three primers with sequence 5'-AAAGTCGCTCTGAGTTGTTAT-3', 
5'-GCGAAGAGTTTGTCCTCAACC-3' and 5'-GGAGCGGGAGAAATGGATATG-
3'.  The PCR program 94°C for 4 minutes, 43 cycles of 94°C for 30 seconds, 
67°C for 30 seconds and 72°C for 30 seconds and held at 4°C yields 2 
fragments, one that is 600-bp and that is 275-bp.  A single 600-bp band indicates 
WT alleles, one 600-bp fragment and one 275-bp fragment indicates a Rosa26R 
heterozygous genotype and a single 275-bp fragment indicates a Rosa26R 
homozygous genotype.    
 
Mechanical Wire Carotid Artery Injury. 
The carotid arteries of 12-15 week old C57BL/6 WT and Nf1+/- male mice 
were mechanically injured by use of a beaded guidewire as previously described 
with minor modifications (72, 167).  In brief, animals were anesthetized by 
inhalation of isoflurane (2%)-oxygen (98%) mixture.  Under a dissecting 
microscope (Leica, Bannockburn, IL), the entire left carotid artery was exposed 
via an anterior incision of the neck.  Microvascular clamps were used to 
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temporarily occlude the common and internal carotid artery and a 6/O silk 
ligature was used to tie off the distal external carotid artery.  An epoxy resin-
beaded probe (0.45 mm to 0.6 mm diameter beads) was introduced through a 
transverse arteriotomy in the external carotid artery.  The probe was inserted and 
withdrawn into the common carotid artery three times with rotation to denude the 
endothelium and stretch the artery approximately 2 fold.  The external carotid 
artery was immediately ligated proximal to the arteriotomy site.  Microvascular 
clamps were removed and normal blood flow through the common carotid and 
internal carotid artery was reestablished.  The skin was closed with running 6/O 
suture.  The mice recovered for 21 days with no sign of stroke or surgical 
complications.    
 
Imatinib Mesylate Administration 
When stated, imatinib mesylate (50 mg/kg/day; Novartis International AG, 
Basel, Switzerland) was administrated once per day by intraperitoneal (I.P.) 
injection.  Imatinib mesylate treatment began 3 days prior to carotid injury and 
continued through day 7 post injury.  Mice recovered to 21 days post injury.  
Phosphate buffered saline (PBS; Invitrogen, Grand Island, NY) was given in an 






Histopathology and Immunohistochemistry for Mechanical Wire Carotid 
Injury. 
 Twenty-one days after carotid injury, mice were anesthetized with 1.25% 
Avertin (Sigma-Aldrich, St. Louis, MO) and were perfusion fixed in situ with PBS 
for 5 minutes followed by 4% paraformaldehyde in PBS (pH 7.3) for 10 minutes 
at a constant pressure of 100 mmHg.  The injured left and control uninjured right 
common carotid arteries were excised under a dissecting microscope, fixed in 
4% paraformaldehyde for 8-12 hours at 4°C and embedded in paraffin or snap-
frozen in O.C.T. (Sakura Finetek U.S.A., Inc. Torrance, CA) in liquid nitrogen.  
Serial 5 µm cross-sections were made at 100 µm intervals across the length of 
the artery.  Hematoxylin/Eosin (H&E) staining was conducted according to 
standard methods (Anatech, Ltd., Battle Creek, MI).  
 For immunostaining, de-waxed and hydrated sections were blocked for 
endogenous peroxidase activity with 3% hydrogen peroxide in PBS following 
antigen retrieval in Antigen Unmasking Solution (Vector Laboratories, 
Berlingame, CA) at 95°C.  Sections were blocked in 3% bovine serum albumin 
(BSA; Sigma, St. Louis, MO) for 1 hour at room temperature and were stained for 
smooth muscle cells (anti-α-SMA; Sigma, 1:400), cellular proliferation (anti-Ki67; 
DAKO Corp, Carpinteria, CA, 1:50), or Erk phosphorylation (anti-phospho-Erk; 
Cell Signaling, Danvers, MA, 1:100) for 1 hour at room temperature.  Purified 
class- and species-matched immunoglobulins (BD Pharmingen, San Jose, CA) 
were used for isotype controls.  Sections were incubated with the appropriate 
biotinylated secondary antibody (Vector Laboratories) followed by incubation with 
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either 3,3′-Diaminobenidine (DAB; Vector Laboratories) for 5 min and 
counterstained with hematoxylin, or were mounted in 90% glycerol/10% PBS, pH 
8.0, containing, 6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma) to 
permit nuclear identification.  Sections were examined and images of sections 
were collected using a Zeiss Axioskop microscope (Carl Zeiss, Chester, VA) with 
a 20X or 40X CP-ACHROMAT/0.12NA objective.  Images were acquired using a 
SPOT RT color camera (Diagnostic Instruments, Sterling Heights, MI).   
Percent positive Ki67 cells in the neointima was calculated as: (total 
number Ki67 positive cells in neointima/total cell number in neointima)*100.  
Percent positive phospho-Erk cells in the neointima was calculated as (total 
number phospho-Erk positive cells in neointima/total cell number in 
neointima)*100. 
 
Carotid Artery Ligation. 
Carotid artery injury was induced by complete ligation of the left common 
carotid artery as previously described (161).  Briefly, mice were anesthetized by 
inhalation of isoflurane (2%)-oxygen (98%) mixture.  Under a dissecting scope 
(Leica), the entire left carotid artery was exposed through a midline incision of the 
neck.  The common carotid artery was completely ligated just proximal to the 
bifurcation using 6-O silk suture (Fine Science Tools, Foster City, CA).  Mice 





Bone Marrow Transplantation. 
Femurs and tibias from WT and Nf1+/- mice that ubiquitously express GFP 
were flushed with Iscove’s Modified Dulbeccos Medium (IMDM, Invitrogen, 
Carlsbad, CA).  Whole, unfractionated bone marrow was collected and washed 
and re-suspended in IMDM.  Male, 12 week old recipient WT and Nf1+/- mice 
were conditioned by lethal irradiation (1100 rads) given at a 700 rad dose 
followed by a 400 rad dose 4 hours later.  Unfractionated bone marrow cells 
(5x10^6 cells) were injected via tail vein into conditioned recipients.  After a four 
month reconstitution period, peripheral blood was collected via tail vein bleed to 
determine percent engraftment.  Red blood cells were lysed (Qiagen, 
Germantown, MD) and mononuclear cells (MNCs) were re-suspended and 
analyzed by flow cytometry using FACS Calibur (BD, Franklin Lakes, NJ) and 
data was analyzed using FlowJo software, version 8.7.3 (Tree Star, Ashland, 
OR).  MNCs isolated from a non-transplant control were used for a negative 
control and only mice with greater than 85% engraftment were used for 
experiments. 
 
Histopathology and Immunohistochemistry for Carotid Artery Ligation. 
Twenty-eight days post ligation, whole ligated and contralateral uninjured 
carotid arteries were harvested from mice.  Mice were anesthetized with 1.25% 
Avertin (Sigma-Aldrich, St. Louis, MO) and were perfusion fixed at constant 
pressure (100mmHg) with 10 mL of 0.9% sodium chloride followed by Z-fix 
solution (Anatech) for 5 minutes at a constant pressure of 100 mmHg.  Under a 
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dissecting scope, whole carotid arteries were excised then subsequently fixed 
overnight at 4°C in Z-fix solution and paraffin embedded.  Serial, 5 μm arterial 
cross-sections were collected every 200μm across the length of the carotid 
artery.  H&E staining was performed according to standards methods (Anatech).  
Animals that showed sign of clot or thrombus formation due to carotid ligation 
were excluded from the study.    
For immunohistochemistry, paraffin-embedded sections were de-waxed 
followed by enzymatic (20μg/mL Proteinase K, Roche, Indianapolis, IN) antigen 
retrieval for 10 minutes at 37°C.  Sections were blocked with Protein Block 
(Dako, Carpinteria, CA) for 1 hour at room temperature followed by incubation 
with anti-GFP (Abcam, Cambridge, MA, 1:1000), or anti-Mac3 (BD Pharmingen, 
San Jose, CA, 1:50) primary antibodies.  Sections were incubated with the 
appropriate secondary antibody (Vector Laboratories) and visualized DAB 
development and counterstained with hematoxylin. 
For immunofluoresence co-staining, paraffin-embedded sections were de-
waxed followed by enzymatic antigen retrieval at 37°C for 10 minutes.  Sections 
were blocked with M.O.M. reagents according to manufacturer’s 
recommendations (Vector Laboratories) and incubated with anti-GFP (Abcam, 
1:1000) primary antibody followed by the appropriate biotinylated secondary 
antibody.  The sections were then co-incubated with anti-α-SMA (Sigma, 1:400) 
and AlexaFluor 546 strepavidin conjugated antibody (BD Pharmingen) and 




Sections were visualized on a Leica DM4000 B microscope with a 20X or 
40X objective and images were captured using a SPOT RT color camera. 
 
Morphometric Analysis. 
 For morphometric analyses, images of H&E stained cross-sections of 
injured and control arteries were analyzed using Metamorph 6.1 (Universal 
Imaging System Corp, Westerchester, PA).  Lumen area, area inside internal 
elastic lamina (IEL) and area inside external elastic lamina (EEL) were measured 
for each cross-section.  The neointima area was calculated by subtracting the 
lumen area from the IEL area and the media area was calculated by subtracting 
the IEL area from the EEL area.  The intima-to-media (I/M) ratio was calculated 
as intima area divided by media area(165).  For mechanical wire injury, 5-10 
sections along the length of each artery, 100 μm apart were measured by a 
person blinded to animal genotypes.  The average neointima area and average 
I/M ratio were calculated for both the uninjured and injured artery.  An average 
was neointima area and I/M ratio was calculated for each genotype.  Percent 
lumen stenosis was calculated as: (intima area/IEL area)*100.  For the carotid 
ligation model, H&E stained arterial cross-sections at 400 μm, 800 μm, and 1200 
μm proximal to the ligation were measured for neointima area and I/M ratio as 
described.  The measurements from the three sections were averaged for each 
animal and an average neointima area and I/M ratio were calculated for each 




Identification of Murine Monocytes by Flow Cytometry. 
 Peripheral blood from WT and Nf1+/- mice was collected via tail vein bleed 
into EDTA microtainer tubes (BD).  Peripheral blood was diluted 1:10 with PBS 
followed by red blood cell lysis (Qiagen).  MNCs were washed in PBS and 
blocked with mouse FcR Blocking Reagent (Milltenyi Biotec, Auburn, CA) for 30 
minutes at 4°C.  MNCs were incubated with anti-Cd11b phycoerythrin (PE; BD 
Pharmingen) and anti-F4/80 fluoroscein isothyocyanate (FITC, Invitrogen) for 30 
minutes at 4°C.  Stained MNCs were acquired on a FACS Calibur (BD).  50,000 
events were collected per sample and analyzed using FlowJo software, version 
8.7.3. 
 
Quantification of Cytokine and Chemokine Levels in Murine Peripheral 
Blood. 
 Peripheral blood from WT and Nf1+/- mice was collected via tail vein bleed 
into EDTA microtainer tubes (BD).  Samples were centrifuged at 2,000g for 20 
minutes at 4°C.  Plasma was isolated and stored at -80°C until use.  IL-1β, IL-6, 
IL-10, TNFα, IFN-γ, GM-CSF, MCP-1 and M-CSF were quantified by using a 
custom Milliplex Cytokine kit (Millipore, Billerica, MA) according to manufacturer’s 
recommendations.  Samples were analyzed by a Luminex200 version 2.3 and 
the StatLIA Immunoassay Analysis Software (Brendan Technologies, Inc., 
Carlsbad, CA) with a 5-parameter logistic curve fitting method was used to 
calculate sample concentrations.  Concentrations below the minimum detectable 




 NF1 patients were recruited through the Indiana University 
Neurofibromatosis Clinic at Riley Hospital for Children.  All patients had a 
medical history and physical examination performed to confirm the diagnosis of 
NF1 using standard NIH clinical criteria (193).  Patients with a personal history of 
cancer, currently using anti-cancer drugs or patients who were pregnant were 
excluded from the study.  All patients gave informed consent prior to their 
participation in the study. 
 
PFC Analysis of Peripheral Blood MNCs. 
Blood samples were collected from NF1 patients (37.6±9.7 years) and age 
and sex-matched healthy controls (40.2±8.1 years) into EDTA Vacutainer tubes 
(BD Biosciences).  MNCs were isolated from 16 mLs of peripheral blood by 
density centrifugation using Ficoll-Paque Plus (GE Healthcare, Pittsburgh, PA) as 
previously described (194).  A total of 10 million MNCs were resuspended in PBS 
with 2% FBS and incubated with human FcR Blocking Reagent (Miltenyi Biotec, 
Auburn, CA) for 10 minutes at 4°C.  Following blocking, MNCs were incubated 
for 30 minutes at 4°C with the following primary conjugated monoclonal 
antibodies: anti-human CD14 PECy5.5 (Abcam), anti-human CD45 
allophycocyanin (APC)-AlexaFluor 750 (Invitrogen), and anti-human CD16 
PECy7 (BD Pharmigen) as well as the live/dead marker ViVid (Invitrogen).   
Following staining, MNCs were washed 2 times with PBS with 2% FBS and fixed 
in 1% formaldehyde (Sigma-Aldrich) for a minimum of 24 hours.  Stained MNC 
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samples were acquired on a BD LSRII flow cytometer (BD, Franklin Lakes, NJ, 
USA) equipped with a 405nm violet laser, 488nm blue laser and 633nm red 
laser.  At least 300,000 events were collected for each sample.  Data was 
collected uncompensated and analyzed using FlowJo software, version 8.7.3 
(Tree Star, Inc., Ashland, OR, USA).  The Institutional Review Board at the 
Indiana University School of Medicine approved all protocols.    
 
Quantification of Cytokines in Patient Plasma Samples.   
Blood samples were collected from NF1 patients (17±2 years, n=6) and 
healthy age-matched controls (18.5±3.4 years, n=7) EDTA Vacutainer tubes (BD 
Biosciences).  Plasma was isolated from 3 mLs of blood by centrifugation at 900g 
for 10 minutes at 4°C.  Plasma was aliquoted and stored at -80°C until use. IL-
1β, IL-6, IL-10, TNFα, GM-CSF, MCP-1, IFN-γ and fractalkine were quantified by 
using a custom Milliplex Cytokine kit (Millipore, Billerica, MA) according to 
manufacturer’s recommendations.  Only plasma samples that had not undergone 
a freeze/thaw cycle were analyzed.  Samples were analyzed by a Luminex200 
version 2.3 and the StatLIA Immunoassay Analysis Software (Brendan 
Technologies, Inc., Carlsbad, CA) with a 5-parameter logistic curve fitting method 
was used to calculate sample concentrations.  Concentrations below the 
minimum detectable concentration were set equal to the minimum detectable 
concentration.  The Institutional Review Board at the Indiana University School of 





 All values are presented as mean ± S.E.M.  Intima area and I/M ratio 
analysis was assessed by One-way ANOVA with a Tukey post-test was 
performed using GraphPad InStat version 3.00 (GraphPad Software, San Diego 
California USA).  Percent lumen stenosis and percent Ki67 positive cells analysis 
were assessed by Student's unpaired t test with Welch correction.  Percent 
phopsho-Erk positive cells were assessed by Student's unpaired t test.  Percent 
GFP positive cells were analyzed by One-way ANOVA with a Tukey post-test.  
Patient and control plasma concentrations of IL-1β were assessed by the non-
parametric Mann-Whitney test.  Patient and control plasma concentrations of IL-6 
were log-transformed for normal distribution and assessed by Student’s unpaired 
t test.  Fractalkine levels were assessed by Student's unpaired t test with Welch 
















Development of an In Vivo Model of NF1 Vasculopathy. 
 In order to fully understand NF1 vasculopathy, an in vivo model needed to 
be developed that recapitulated the human phenotype.  The following criteria was 
established to ensure an expandable model murine was developed to interrogate 
NF1 vasculopathy: 
1. The genotype of the animal or cell lineage being investigated must 
agree with experimental findings described in NF1 patients. 
2. The established model must be reproducible and provide consistent 
results. 
3. The vascular phenotype identified in the experimental model must 
recapitulate the vascular lesions described in NF1 patients.     
 
 NF1 patients are heterozygous for NF1 and loss of heterozygosity has not 
been described in ECs or VSMCs.  Therefore, we utilized Nf1+/- mice which are 
genetically similar to NF1 patients, having one functional allele of the Nf1 gene.  
Nf1+/- mice develop normally and are phenotypically similar to WT mice.  The 
vasculature of Nf1+/- mice shows no vascular lesion formation without external 
manipulation.  To induce neointima formation, two well-established models of 
arterial injury have been described which include a mechanical injury model and 
a hemodynamic injury model.  The mechanical injury model mimics vascular 
lesion formation by denuding the endothelium through the insertion of either a 
balloon catheter (156) or a flexible wire (157) into the artery.  In this model, the 
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loss of the endothelium results in platelet aggregation on the exposed 
extracellular matrix followed by leukocyte recruitment (157).  Platelets are a 
potent source of PDGF-BB (158, 159), which stimulates VSMC migration from 
the media into the intima area (61, 62, 160).  As originally described, VSMC 
proliferation is at the highest rate 1-2 weeks post injury and reendothelialization 
of the artery is complete within 3 weeks (157).  This model is technically 
challenging with the caveat that breaking of the internal elastic lamina during 
injury can result in robust neointima formation mediated through a different 
mechanism than that of just endothelial denudation.  The second injury model, a 
ligation model, induces neointima formation through changes in hemodynamic 
forces (161).  In this model, the artery is ligated to stop the net forward flow of 
blood.  Changes in shear stress activate the endothelium to express adhesion 
molecules which facilitate leukocyte transmigration.  Further, the near static 
conditions in the ligated artery allow for platelet aggregation on the endothelium 
that can stimulate VSMC migration and proliferation into the intima.  The ligation 
model is technically easier and more consistent than the mechanical injury model 
and mimics vascular lesion formation that has been described in areas of low or 
altered shear stress in patient populations (162, 163).   
 The vascular injury models described have been utilized in numerous 
genetically engineered mice to demonstrate the role of adhesion molecules, 
signaling molecules, growth factors etc. in vascular lesion formation.  Along with 
information about the mechanism of neointima formation, these models have 
identified that murine strain and sex have a direct role in the size of vascular 
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lesion formation in response to injury.  Strain dependent studies have been 
conducted with carotid artery injury using both the mechanical wire injury model 
and arterial ligation model (164, 165).  In both studies, the C57BL/6 strain had 
one of the lower responses in terms of neointima area and intima-to-media (I/M) 
ratio and the 129/SvJ strain had an intermediate response.  In order to determine 
which strain is appropriate to identify the role of a specific protein in neointima 
formation, it is important to understand whether the mutant mouse will have a 
larger or smaller response than the WT controls.  When using the C57BL/6 
strain, the injured artery from the WT mouse does not have a significantly larger 
neointima area than the uninjured artery, therefore this strain is a poor choice if a 
reduction in neointima is the expected result from genetic manipulation.  Further, 
in response to vascular injury, female mice have been shown to have reduced 
neointima area compared to male mice of the same genotype and strain (166).  
Tolbert et al. reported that ovariectomy of the female mice corrected the sex-
dependent difference and that exogenous estrogen attenuated neointima 
formation in these mice (166).  Therefore, the use of male mice eliminates the 
variation in response to vascular injury due to the effects of estrogen.              
 
Nf1 +/- Mice Have Increased Neointima Formation and Vessel Lumen 
Occlusion in Response to Mechanical Arterial Injury. 
 Heterozygous inactivation of Nf1 increases VSMC proliferation and 
migration in response to PDGF-BB stimulation in vitro (48), which are cellular 
functions linked to neointima formation in vivo (63, 64, 68-72).  Therefore, based 
on these prior studies, we tested whether Nf1+/- mice had increased neointima 
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formation in response to mechanical arterial injury in vivo compared to WT 
controls utilizing a well established surgical model (167).  The C57BL/6 murine 
strain was utilized for these experiments since previous studies indicate that 
C57BL/6 mice are more resistant to neointima formation in response to injury 
compared to other strains (165).  Therefore, we hypothesized that use of 
C57BL/6 mice would allow us to interrogate whether Nf1 haploinsufficiency would 
enhance neointima formation on a relatively resistant murine genetic strain.   
 Briefly, the endothelium of the common carotid artery of WT and Nf1+/- mice 
was denuded using a beaded wire and the mice were allowed to recover for 21 
days postoperatively.  Whole carotid arteries were then harvested and analyzed 
to quantify the animal’s response to injury (Figure 7).  For each animal, the 
contralateral carotid artery served as an uninjured control compared to the 
injured vessel.  To quantitate differences between the two experimental 
genotypes, morphometric analysis on arterial cross-sections was completed by 
measuring lumen, intima and media area.  From these measurements, the I/M 
ratio was calculated for the injured and uninjured arteries.  The I/M ratio is a 
widely used measurement to predict the development of cardiovascular morbidity 
(168).  Of note, animals in which the internal elastic lamina was damaged by the 








Figure 7.  Schematic of experimental strategy for assessing neointima 














 Histological examination of the uninjured carotid arteries from WT and Nf1+/- 
mice demonstrated the absence of neointima formation and revealed no 
structural differences in vessel architecture between the two experimental 
genotypes (Figure 8A).  However, in response to arterial injury, Nf1+/- mice had 
increased vessel occlusion compared to WT controls (Figure 8A).  A 
representative low and high power image of a hematoxylin-eosin (H&E) stain of 
an arterial cross section of uninjured and injured vessels harvested from WT and 
Nf1+/- mice is shown in Figure 8A.  Detailed morphometric analysis revealed that 
the injured arteries isolated from Nf1+/- mice had a five-fold increase in intima 
area compared to WT controls (Figure 8B).  No significant difference was 
observed in the media area in response to injury between the two genotypes 
(Figure 9) indicating Nf1+/- mice have increased accumulation of cells in the 
intima area resulting in partial lumen occlusion.  Of note, the C57/BL6 WT mice 
formed a small neointima after arterial injury, which is similar to previously 
published reports utilizing this murine strain(165).  Based on intima and media 
area measurements, the average I/M ratio of the injured arteries harvested from 
Nf1+/- mice was 3.5 fold higher than WT controls (Figure 8C).  Further, Nf1+/- mice 
had a six fold increase in percent lumen stenosis in response to injury compared 
to WT mice (Figure 8D).  Therefore, this data clearly demonstrates that 
heterozygous inactivation of Nf1 greatly accelerates neointima formation and 















Figure 8.  Histological and morphometric analysis of neointima formation in 
WT and Nf1+/- mice.  A)  Representative H&E stained carotid artery cross-
sections from WT (top panel) and Nf1+/- mice.  Red arrows indicate neointima 
boundaries.  Scale bars represent 50 μm.  B)  Quantification of neointima area of 
uninjured and injured carotid arteries from WT and Nf1+/- mice.  Data represent 
mean neointima formation of 5 cross-sections ± SEM, n=5.  For Nf1+/- uninjured 
vs. injured, *p<0.05, and for WT injured vs. Nf1+/- injured, **p<0.05 by one way 
ANOVA.  C)  Quantification of I/M ratio of uninjured and injured carotid arteries 
from WT and Nf1+/- mice.  Data represent mean I/M formation of 5 cross-sections 
± SEM, n=5.  For Nf1+/- uninjured vs. injured, *p<0.01, and for WT injured vs. 
Nf1+/- injured, **p<0.05 by one way ANOVA.  D)  Quantification of percent carotid 
artery stenosis for injured WT and Nf1+/- mice.  Data represent the mean percent 
stenosis of 5 cross-sections ± SEM, n=5, *p<0.04 by Student’s unpaired t test 




























Figure 9.  Morphometric analysis of media area in WT and Nf1+/- mice.   
Quantitative analysis of media area of injured carotid arteries from WT and Nf1+/- 























Nf1 +/- Mice Have Increased Numbers of VSMCs in the Evolving Neointima. 
 PDGF-BB binding to its receptor activates both the Ras-Erk and PI-3 
kinase-Akt signaling pathways, which regulate the proliferation and migration of 
VSMCs (169-171).  Our previous data demonstrates that heterozygous 
inactivation of Nf1 increases both murine and human VSMC proliferation and 
migration via hyperactivation of the canonical Ras-Erk pathway and not the Ras-
PI-3 kinase-Akt pathway in vitro (48).  Therefore, in order to better understand 
the mechanism of increased neointima formation in Nf1+/- mice, we utilized 
immunohistochemistry to identify VSMCs within the neointima, proliferating 
resident neointima cells, and Erk activation after arterial injury. 
 In response to arterial injury, the evolving neointima in both WT and Nf1+/- 
mice was composed primarily of VSMCs, as detected by immunohistochemical 
staining of cells with an anti-alpha smooth muscle actin (α-SMA) antibody in 
arterial cross sections (Figure 10).  For both WT and Nf1+/- mice, VSMCs 
accounted for at least 75 percent of the cells in the neointima, which is consistent 
with previously published reports (78, 172).  This may be an underestimation of 
VSMCs in the neointima because vascular injury produces phenotypic change in 
VSMCs from a quiescent, differentiated cell to a cell with enhanced proliferation 
and migration which downregulates the expression of certain proteins, including 
α-SMA (173).  The accumulation of VSMCs within the intima area of recapitulates 
the phenotype described in case reports from NF1 patients with vascular lesions 



















Figure 10.  α-SMA analysis of carotid arteries from WT and Nf1+/- mice.  
Representative photomicrographs of uninjured (left panel) and injured (right 
panel) carotid arteries from WT (top panel) and Nf1+/- (bottom panel) mice 
stained with α-SMA (red).  Cell nuclei are counterstained with DAPI (blue) and 
tissue autofluorescence is visible (green).  White arrows indicate neointima 
boundaries.  White boxes indicate areas magnified in inset.  Scale bars represent 



















Nf1 +/- Mice Have Increased Cellular Proliferation in the Evolving Neointima. 
 Intimal hyperplasia in response to arterial injury requires the migration of 
VSMCs from the media area of the vessel in to the intima area where they 
proliferate.  To determine if Nf1+/- VSMCs had increased proliferation in response 
to arterial injury, cellular proliferation in the neointima was determined by 
immunohistochemical staining of arterial cross-sections for the presence of Ki67, 
a nuclear protein that is expressed in all cells active in cell cycle (174).  The 
injured vessels harvested from Nf1+/- mice had increased cellular proliferation in 
the neointima compared to WT controls (Figure 11A).  Specifically, Nf1+/- injured 
vessels had an approximately 20 fold increase in the percent of proliferating cells 
in the neointima, which expressed the Ki67 antigen, compared to WT controls 21 
days post injury (Figure 11B).  Since the majority of the cells within the neointima 
are VSMCs, the increased neointima area in Nf1+/- mice compared to WT mice 
can be attributed to increased proliferation of VSMCs in response to mechanical 
injury.  Of note, there was little cellular proliferation detected in the uninjured 
arteries from either Nf1+/- or WT mice indicating that in the absence of a stimulus 






















Figure 11.  Analysis of cellular proliferation within the neointima of injured 
carotid arteries from WT and Nf1+/- mice.  A)  Representative 
photomicrographs of uninjured (left panel) and injured (right panels) carotid 
arteries from WT (top panels) and Nf1+/- (bottom panels) stained with anti-Ki67 
(brown) and hematoxylin (blue).  Black boxes in middle panel indicate areas that 
are magnified in far right panels.  Red arrows indicate neointima boundaries.  
Black arrows represent positive Ki67 staining of proliferating cells.  Scale bars 
represent 50 μm.  Results are representative of 5 independent experiments.  B)  
Quantification of percent Ki67 positive cells within the neointima of injured carotid 
arteries from WT and Nf1+/- mice calculated as (total Ki67 positive cells in 
neointima/total number of cells in neointima)*100.  Data represent the mean 
percentage of Ki67 positive cells in the neointima ± SEM, n=3, *p<0.005 by two-













Nf1 +/- Mice Have Increased Erk Phosphorylation in the Evolving Neointima. 
 The increased proliferation detected 21 days post-injury in the Nf1+/- mice 
suggests that the cells within the neointima have hyperactive Ras-ERK signaling, 
a pathway known to control cellular proliferation.  Activation of the Ras-Erk 
pathway in vivo in response to arterial injury was determined by staining injured 
arterial cross sections with an antibody directed against phosphorylated-Erk.  
Consistent with increased numbers of VSMCs and cellular proliferation in the 
neointima, Nf1+/- mice had increased Erk phosphorylation compared to WT 
controls 21 days after arterial injury (Figure 12).  Similar to results seen with 
cellular proliferation, baseline levels of Erk phosphorylation were minimal in the 
uninjured arteries and there was no difference detected between the WT and 
Nf1+/- mice.  The hyperactivation of the Ras-Erk pathway in response to arterial 
injury provides a molecular target for understanding the mechanism of NF1 
























Figure 12.  Analysis of Erk phosphorylation within the neointima of injured 
carotid arteries of WT and Nf1+/- mice.  A)  Representative photomicrographs 
of uninjured (left panels) and injured (right panels) carotid arteries from WT (top 
panels) and Nf1+/- (bottom panels) mice stained with anti-phospho-Erk (brown) 
and counterstained with hematoxylin (blue).  Black boxes in middle panel indicate 
areas magnified in far right panel.  Red arrows indicate neointima boundaries.  
Black arrowheads represent positive phosphor-Erk staining.  Data represent 5 
independent experiments.  Scale bars represent 50 μm.  B)  Quantification of 
percent phosphorylated-Erk positive cells within the neointima of injured carotid 
arteries of WT and Nf1+/- mice.  Data represent mean percentage of 
phosphorylated-Erk positive cells in the neointima ± SEM, n=3, *p<0.04 by two-














Administration of Imatinib Mesylate Inhibits Neointima Formation in Nf1 +/- 
Mice After Mechanical Arterial Injury. 
 Imatinib mesylate is a potent inhibitor of the PDGF-BB signaling axis in 
VSMCs and prevents neointima formation and aneurysms in vivo in mice 
genetically predisposed to diverse vasculopathies (63).  Given our prior 
experimental observations implicating hyperactivation of the PDGF-BB-Ras-Erk 
signaling pathway in the neointima formation in Nf1+/- mice, we tested whether 
pre-administration of imatinib mesylate would inhibit neointima formation in Nf1+/- 
mice after arterial mechanical injury (Figure 13).  We utilized an imatinib 
mesylate treatment protocol which had previously been shown to prevent 
neointima formation in other murine models of vascular disease (115).  
Specifically, either phosphate buffered saline (PBS) or 50 mg/kg imatinib 
mesylate was administered daily to WT and Nf1+/- mice intraperitoneally 
beginning 3 days prior to arterial injury and continued for 7 days post injury.  Mice 
were then sacrificed 21 days postoperatively for analysis.   
 In response to carotid injury, imatinib mesylate treatment greatly reduced 
neointima formation in Nf1+/- mice compared to PBS treatment (Figure 14A).  
Specifically, imatinib mesylate treated Nf1+/- mice had a four-fold reduction in I/M 
ratio compared to PBS treated Nf1+/- mice (Figure 14B) in response to carotid 
injury.  No significant difference was seen in response to injury in the I/M ratios of 
WT mice when comparing PBS to imatinib mesylate treatment.  This is consistent 
with the fact that C57BL/6 WT mice are resistant to neointima formation in 
response to mechanical injury (165, 172).  Further, immunohistochemistry 
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indicates that imatinib mesylate treatment reduced cellular proliferation as well as 
Erk phosphorylation in Nf1+/- mice in response to injury compared to PBS 
treatment (Figure 15).  Thus, this data indicates that enhanced neointima 
formation in Nf1+/- in response to vascular injury is mediated via an imatinib 
mesylate sensitive pathway.  While we have identified a pharmacological 
antagonist of neointima formation in Nf1+/- mice, the cellular mechanism of 
neointima formation is unknown because imatinib mesylate inhibits more than 
one receptor.  Therefore, to fully understand NF1 vasculopathy, the predominate 


















Figure 13.  Schematic of imatinib mesylate inhibition of neointima 





















Figure 14.  Histological and morphometric analysis of injured carotid 
arteries from imatinib mesylate-treated WT and Nf1+/- mice.  A)  
Representative photomicrographs of H&E-stained carotid arteries from WT (top 
panels) and Nf1+/- (bottom panels) mice 21 days following no injury and PBS 
treatment (left panels), injury and PBS treatment (middle panels), or injury and 
imatinib mesylate treatment (right panels).  Red arrows indicate boundary of 
neointima.  Scale bars represent 50 µm.  Results are representative of 5 
independent experiments.  B)  I/M ratio of injured carotid artery cross-sections 
from PBS and imatinib mesylate-treated WT and Nf1+/- mice.  Data represent 
mean I/M ratio of 5 cross-sections ± SEM, n=4 to 6 mice.  For Nf1+/- uninjured vs. 
injured with PBS treatment, *p<0.001; for Nf1+/- injured with PBS vs. injured with 
imatinib mesylate treatment, **p<0.001; and for WT injured with PBS treatment 


























Figure 15.  Analysis of α-SMA, Ki67, and Erk phosphorylation within the 
neointima of injured carotid arteries from imatinib mesylate-treated Nf1+/- 
mice.  Representative photomicrographs of α-SMA staining (left panels) of 
carotid artery cross-sections from injured Nf1+/- PBS-treated (top panels) and 
Nf1+/- imatinib mesylate-treated (bottom panels) mice.  α-SMA staining is seen in 
red, DAPI nuclear dye is blue and murine tissue autofluorescence is green.  
White arrows indicate neointima boundary.  White boxes indicate area magnified 
in inset.  Representative images of Ki67 (middle panels) and phoshophorylated-
Erk (right panels) staining of carotid artery cross-sections counter-stained with 
hematoxylin (blue).  Red arrows indicate neointima boundary.  Black arrowheads 
represent positive Ki67 or phosphorylated-Erk staining (brown).  Black boxes 
indicate areas magnified in insets.  Results are representative of 5 independent 













Heterozygous Inactivation of Nf1 in ECs and VSMCs Alone is Insufficient to 
Recapitulate Neointima Formation of Nf1+/- Mice. 
In order to determine the cellular mechanism of NF1 vasculopathy, we 
initially generated mice, utilizing cre/lox technology, that were heterozygous for 
Nf1 in ECs alone or VSMCs alone.  Briefly, Nf1flox/flox mice, which contain 
conditional Nf1 alleles susceptible to Cre mediated recombination, were crossed 
with either Tie2cre or SM22cre mice to generate Nf1flox/+;Tie2cre and 
Nf1flox/+;SM22cre progeny (Figure 16).  Tie2cre mice express Cre recombinase 
under the control of the Tek promoter, which is expressed uniformly in ECs 
resulting in deletion of floxed sequences in ECs (175).  In the SM22cre mice, Cre 
recombinase expression is driven by the smooth muscle cell specific promoter, 
transgelin, resulting in deletion of floxed sequences in smooth muscle cells, 
including VSMCs in the carotid artery (176).  Cre expression was mapped 
utilizing the Rosa26 reporter mouse, which expresses lacZ in response to Cre 
expression (177) to demonstrate the generation of experimental mice that are 
heterozygous for Nf1 only in ECs (Nf1flox/+;Tie2cre) or VSMCs (Nf1flox/+;SM22cre) 
with all other cell lineages containing both Nf1 alleles (Figure 16).   
To interrogate the role of Nf1 in ECs and VSMCs, Nf1flox/+;Tie2cre and 
Nf1flox/+;SM22cre mice, respectively, underwent carotid artery ligation and 
analysis for neointima formation along with experimental controls.  Carotid artery 
ligation is a well-established model that induces neointima formation through 
changes in hemodynamic forces (161).  Briefly, the common carotid artery was 
completely ligated proximal to the bifurcation and the mice recovered for 28 days 
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post-operatively.  Whole ligated carotid arteries along with the contralateral 
uninjured carotid arteries were harvested from each animal and analyzed for 
neointima formation as previously described (161).   
Histological analysis of H&E stained arterial cross-sections from the 
uninjured carotid artery demonstrated that WT, Nf1+/-, Nf1flox/+;Tie2cre and 
Nf1flox/+;SM22cre are not structurally different and showed no sign of neointima 
formation (Figure 17).  Analysis of the ligated carotid arteries indicated that only 
Nf1+/- mice have significantly enhanced neointima formation in response to 
arterial injury (Figure 17 and 18) with no difference in neointima formation 
detected between WT, Nf1flox/+;Tie2cre and Nf1flox/+;SM22cre mice.  Specifically, 
Nf1+/- mice have a five-fold increase in I/M ratio compared with WT, 
Nf1flox/+;Tie2cre and Nf1flox/+;SM22cre mice (Figure 17c).  This data demonstrates 
that heterozygous inactivation of Nf1 in ECs or VSMCs alone is insufficient for 
neointima formation in Nf1+/- mice after vascular injury.   












Figure  16.  Breeding scheme for the generation of Nf1flox/+;Tie2cre and 
































Figure 17.  Histological and morphometric analysis of WT, Nf1+/-, 
Nf1flox/+;Tie2cre and Nf1flox/+;SM22cre mice.  A)  Representative H&E stained 
cross-sections uninjured (left panel) and injured (right panel) carotid arteries from 
WT, Nf1+/-, Nf1flox/+;Tie2cre and Nf1flox/+;SM22cre mice.  Red arrows indicate 
neointima boundaries.  B)  Quantification of neointima area of uninjured (open 
bars) and injured (black bars) carotid arteries from WT, Nf1+/-, Nf1flox/+;Tie2cre 
and Nf1flox/+;SM22cre mice.  Data represent the mean neointima area of 3 arterial 
cross-sections (400 μm, 800 μm and 1200 μm proximal to the ligation) ± SEM, 
n=4-7, *p<0.001 for Nf1+/- uninjured vs. Nf1+/- injured and Nf1+/- injured vs. WT 
injured, Nf1flox/+;Tie2cre injured and Nf1flox/+;SM22cre injured by one-way 
ANOVA.  C)  Quantification of I/M ratio of uninjured (open bars) and injured 
(black bars) carotid arteries from WT, Nf1+/-, Nf1flox/+;Tie2cre and 
Nf1flox/+;SM22cre mice.  Data represent the mean I/M ratio of 3 arterial cross-
sections (400 μm, 800 μm and 1200 μm proximal to the ligation) ± SEM, n=4-7, 
*p<0.001 for Nf1+/- uninjured vs. Nf1+/- injured and Nf1+/- injured vs. WT injured, 




















Figure 18.  Histological analysis of WT, Nf1+/-, Nf1flox/+;Tie2cre and 
Nf1flox/+;SM22cre mice.  Representative H&E stained arterial cross-sections 
from injured Nf1+/-, Nf1flox/+;Tie2cre and Nf1flox/+;SM22cre mice (left panel).  Black 
box indicates area magnified in right panel.  Red arrows indicate neointima 




















Nf1+/- Bone Marrow Derived Cells Are Necessary and Sufficient for 
Neointima Formation. 
Previous reports demonstrate that infiltration of BMDCs, especially 
leukocytes and macrophages, significantly contributes to neointima formation 
(108, 110, 111).  We have previously reported that Nf1+/- BMDCs have increased 
migration and proliferation in response to multiple growth factors implicated in 
neointima formation (125-127).  Therefore, to test the hypothesis that Nf1+/- 
BMDCs enhanced neointima formation, we utilized adoptive hematopoietic stem 
cell transfer techniques.  BMDCs isolated from Nf1+/- or WT mice that 
ubiquitously express green fluorescent protein (GFP) were transplanted into 
conditioned Nf1+/- or WT recipients to generate Nf1+/- mice with either WT or 
Nf1+/- GFP bone marrow (BM) and WT mice with either WT or Nf1+/- GFP BM 
(Figure 19).  Bone marrow engraftment was determined after four months by 
determining the percent of GFP positive mononuclear cells in peripheral blood by 
flow cytometric analysis.  Mice with greater than 85% engraftment (Figure 20) 












































Figure 20.  Determination of percent bone marrow engraftment.           
A)  Representative forward-scatter (FSC-H) side-scatter (SSC-H) profile of whole 
MNCs from murine peripheral blood.  Black box represents live events gated for 
GFP expression analysis.  B)  Representative histogram of percent GFP 
expression in MNCs.  Red line represents GFP negative control.  Blue line 



















Uninjured arteries from each transplant group were morphologically similar 
and showed no evidence of neointima formation (Figure 21).  In response to 
carotid artery ligation, Nf1+/- mice transplanted with WT BM had a 10 fold 
reduction in neointima area (Figure 21a-b and 22) and a 9 fold reduction in I/M 
ratio compared to Nf1+/- mice reconstituted with Nf1+/- BM (Figure 21c).  Further, 
WT mice transplanted with Nf1+/- BM had a 20 fold increase in neointima area 
(Figure 21b) and I/M ratio (Figure 21b) compared to WT mice reconstituted with 
WT BM.  The observation that transplantation of WT BM into Nf1+/- mice 
completely abrogates neointima formation indicates that heterozygous 
inactivation of Nf1 in BMDCs is necessary and sufficient for neointima formation 






























Figure 21.  Histological and morphometric analysis of WT and Nf1+/- mice 
transplanted with WT and Nf1+/- bone marrow.  A)  Representative H&E 
stained cross-sections of uninjured (left panels) and injured (right panels) carotid 
arteries from WT (top panels) and Nf1+/- (bottom panels) mice transplanted with 
WT or Nf1+/- BM.  Red arrows indicate boundaries of neointima.  B)  
Quantification of neointima area of uninjured (open bars) and injured (black bars) 
carotid arteries from WT or Nf1+/- recipients transplanted with WT or Nf1+/- BM.  
Data represent the mean neointima area of 3 arterial cross-sections (400 μm, 
800 μm and 1200 μm distal to the ligation) ± SEM, n=5-8.  *p<0.001 for WT mice 
transplanted with Nf1+/- BM uninjured vs. WT mice transplanted with Nf1+/- BM 
injured and Nf1+/- mice transplanted with Nf1+/- BM uninjured vs. Nf1+/- mice 
transplanted with Nf1+/- BM injured, and **p<0.001 for WT mice transplanted 
with Nf1+/- BM and Nf1+/- mice transplanted with Nf1+/- BM vs. WT mice 
transplanted with WT BM and Nf1+/- mice transplanted with WT BM injured by 
one-way ANOVA with Tukey post-test.  C)  Quantification of I/M ratio of uninjured 
(open bars) and injured (black bars) carotid arteries from WT or Nf1+/- recipients 
transplanted with WT or Nf1+/- BM.  Data represent the mean I/M ratio of 3 
arterial cross-sections (400 μm, 800 μm and 1200 μm distal to the ligation) ± 
SEM, n=5-8.  *p<0.001 for WT mice transplanted with Nf1+/- BM uninjured vs. WT 
mice transplanted with Nf1+/- BM injured and Nf1+/- mice transplanted with Nf1+/- 
BM uninjured vs. Nf1+/- mice transplanted with Nf1+/- BM injured, and **p<0.001 
for WT mice transplanted with Nf1+/- BM and Nf1+/- mice transplanted with Nf1+/- 
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BM vs. WT mice transplanted with WT BM and Nf1+/- mice transplanted with WT 







































Figure 22.  Histological analysis of WT and Nf1+/- mice transplanted with WT 
and Nf1+/- bone marrow.  Representative H&E stained arterial cross-sections 
from injured WT and Nf1+/- mice that have been transplanted with either WT or 
Nf1+/- bone marrow (BM).  Black box indicates area magnified in lower panel.  





















Nf1+/- Mice Have Evidence of Vascular Inflammation. 
To further understand the cellular mechanism of Nf1+/- BMDCs in 
neointima formation, we identified BMDCs within the neointima in response to 
injury.  Utilizing immunohistochemistry, uninjured and injured carotid artery cross-
sections from each transplant group were co-stained with an anti-GFP antibody, 
to identify BMDCs, and an α-SMA antibody, to identify VSMCs.  We utilized an 
anti-GFP antibody given the amount of autofluorescence inherent in murine 
tissue.  Uninjured carotid arteries for each transplant group showed no 
accumulation of BMDCs within the vessel (Figure 23a).  In response to injury, 
WT mice transplanted with Nf1+/- BM had a 12 fold increase in the accumulation 
of GFP positive BMDCs within the neointima compared to WT mice reconstituted 
with WT BM (Figure 23).  Similarly, Nf1+/- mice transplanted with Nf1+/- BM had a 
14 fold increase in the number of GFP positive BMDCs within the neointima 
compared to Nf1+/- mice transplanted with WT BM (Figure 23b).  Surprisingly, 
despite no difference in neointima size, Nf1+/- mice transplanted with Nf1+/- BM 
had a two fold increase in the number of GFP positive BMDCs within the 
neointima compared to WT mice transplanted with Nf1+/- BM in response to 
carotid ligation (Figure 23b) with no difference in the total number of cells within 
the neointima.  This observation indicates that heterozygous inactivation of Nf1 in 
other cell lineages enhances the recruitment/survival of BMDCs in Nf1+/- mice 
transplanted with Nf1+/- BM.  Of note, arterial cross-sections showed no 
colocalization of GFP positive cells with α-SMA positive cells (Figure 23a) 
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indicating that the VSMCs within the neointima are locally derived and not bone 







































Figure 23.  Identification of VSMCs and BMDCs within the neointima of WT 
and Nf1+/- mice transplanted with WT and Nf1+/- bone marrow.  A)  
Representative photomicrographs of uninjured (left panels) and injured (right 
panels) carotid arteries from WT (top panels) and Nf1+/- (bottom panels) mice 
transplanted with either WT or Nf1+/- bone marrow (BM).  VSMCs are stained 
with anti-α-SMA (red) and anti-GFP (green).  Cell nuclei are visible by DAPI stain 
(blue) and some tissue autofluorescence is visible (green).  White arrows indicate 
neointima boundaries.  Yellow boxes identify area of injured WT and Nf1+/- mice 
transplanted with Nf1+/- BM magnified in the far right panel.  B)  Quantification of 
the total number of GFP positive cells within the neointima of WT and Nf1+/- 
recipient mice after carotid ligation.  Data represents the mean GFP positive cells 
within the neointima 600 μm distal to the ligation ± SEM, n=6.  *p<0.05 for injured 
WT mice transplanted with WT BM vs. injured WT mice transplanted with Nf1+/- 
BM and injured Nf1+/- mice transplanted with WT BM vs. injured Nf1+/- mice 
transplanted with Nf1+/- BM and **p<0.05 for injured WT mice transplanted with 
Nf1+/- BM vs. injured Nf1+/- mice transplanted with Nf1+/- BM by one-way ANOVA 









Heterozygous Inactivation of Nf1 in VSMCs and BMDCs Increased the 
Accumulation of BMDCs Within the Neointima Compared to WT VSMCs.  
In order to determine if heterozygous inactivation in an additional cell 
lineage increased the accumulation of BMDCs in the neointima, we generated 
Nf1flox/+;SM22cre mice reconstituted with Nf1+/- BM.   In response to carotid artery 
ligation, the Nf1flox/+;SM22cre mice transplanted Nf1+/- BM had similar neointima 
formation to both Nf1+/- and WT mice transplanted Nf1+/- BM.  Further, 
immunohistochemistry demonstrated that Nf1flox/+;SM22cre mice reconstituted 
with Nf1+/- BM had equivalent accumulation of BMDCs as the Nf1+/- mice 
transplanted with Nf1+/- BM (Figure 24).  This observation indicates that 
heterozygous inactivation of Nf1 in VSMCs enhanced the recruitment/survival of 
Nf1+/- BMDCs to the site of vascular injury in Nf1+/- mice transplanted with Nf1+/- 
BM compared to WT mice transplanted with Nf1+/- BM.  In future studies in Dr. 
Ingram's lab, the role of neurofibromin in the production of chemokines and 























Figure 24.  Identification of GFP positive BMDCs within the neointima or 
WT, Nf1+/- and Nf1flox/+;SM22cre mice transplanted with Nf1+/- BM.  A)  
Representative photomicrographs of injured carotid arteries from WT (left panel), 
Nf1+/- (middle panel) and Nf1flox/+;SM22cre (right panel) mice transplanted with 
Nf1+/- bone marrow (BM) stained with anti-GFP (brown) and counterstained with 
hematoxylin (blue).  Red arrows indicate neointima boundaries.  B)  
Quantification of the total number of GFP positive cells within the neointima of 
WT, Nf1+/- and Nf1flox/+;SM22cre mice transplanted with Nf1+/- bone marrow.  
Data represents the mean total number of GFP positive cells within the neointima 
600 μm distal to the ligation ± SEM, n=3-6.  *p<0.05 for Nf1+/- vs. WT and 














Heterozygous Inactivation of Nf1 in BMDCs Leads to Vascular Inflammation 
in Response to Injury.   
Carotid artery ligation results in the deposition of platelets and leukocytes 
on the endothelium and the transmigration of leukocytes into the vessel wall.  
Specifically, monocytes and macrophages have been shown to play an essential 
role in neointima formation.  To further define the cellular mechanism of 
neointima formation in WT and Nf1+/- mice reconstituted with Nf1+/- BM, we 
utilized immunohistochemistry to identify the lineage of BMDCs within the 
neointima.  Anti-CD45 immunohistochemistry demonstrated that the BMDCs 
within the neointima were leukocytes (Figure 25).  To further identify the BMDCs 
within the neointima, carotid artery cross-sections were analyzed for the 
presence of lymphocytes and macrophages.  Lymphocytes and macrophages 
are inflammatory cells, which secrete growth factors and cytokines that have 
been implicated in neointima formation in response to injury (178-183).  Further, 
our group has demonstrated that neurofibromin is a critical regulator of Ras 
activation in both lymphocytes and mast cells in vitro and in vivo (126, 184).  
Based on immunohistochemistry, lymphocytes (Figure 26) did not significantly 
accumulate in the neointima or vessel wall of injured arteries in any of the 
experimental genotypes.  However, anti-Mac3 staining of injured carotid arteries 
demonstrated that the majority (>80%) of the GFP positive cells within the 
neointima of all transplant groups were macrophages (Figure 27).  Consistent 
with the results of anti-GFP immunohistochemistry, WT and Nf1+/- mice 
transplanted with WT BM had minimal accumulation of macrophages within the 
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intima area compared with WT and Nf1+/- mice reconstituted with Nf1+/- BM in 
response to injury (Figure 27).  This observation suggests that Nf1+/- BMDCs 
contribute to neointima formation through increased recruitment and/or survival 
of monocytes into the vessel wall where they differentiate into macrophages and 









































Figure 25.  Immunohistochemical analysis of CD45 positive cells within the 
neointima.  Representative photomicrographs of injured carotid arteries from WT 
(left panel) and Nf1+/- (right panel) recipient mice transplanted with Nf1+/- BM 
stained with an anti-CD45 antibody (brown) and counterstained with hematoxylin 
(blue).  Red arrows indicate neointima boundaries.  Black arrows represent 

































Figure 26.  Immunohistochemical analysis of CD3 positive cells within the 
neointima.  Representative photomicrographs of injured carotid arteries from WT 
(top panels) and Nf1+/- (bottom panels) recipient mice transplanted with WT BM 
(left panels) or Nf1+/- BM (right panels) stained with an anti-CD3 antibody (brown) 
and counterstained with hematoxylin (blue).  Red arrows indicate neointima 


































Figure 27.  Identification of macrophage accumulation within the neointima 
of WT and Nf1+/- mice transplanted with Nf1+/- bone marrow.  Representative 
photomicrographs of injured  carotid artery cross sections from WT (top panels) 
and Nf1+/- (bottom panels) mice transplanted with WT (left panels) or Nf1+/- BM 
(middle and right panels) stained with anti-Mac3 antibody (brown) and 
counterstained with hematoxylin (blue).  Red arrows indicate neointima 
boundaries.  Black arrows represent positive Mac3 staining.  Black boxes identify 
area of injured WT and Nf1+/- mice transplanted with Nf1+/- BM that is magnified 
















Based on this observation, we investigated whether heterozygous 
inactivation of Nf1 leads to increased numbers of circulating monocytes.  
Peripheral blood samples were taken from uninjured WT and Nf1+/- mice and 
complete blood count analysis completed.  At baseline, Nf1+/- mice have a 1.5 
fold increase in the percentage of circulating monocytes compared to WT mice 
(Figure 28a).  In order to determine if neurofibromin regulates the migration, 
proliferation and adhesion of macrophages, which are cellular functions critical 
for the recruitment and retention of macrophages in the vessel wall, we isolated 
and purified macrophages from the bone marrow of Nf1+/- and WT mice.  
Stimulation of the macrophages with macrophage colony stimulating factor (M-
CSF), a growth factor critical in neointima formation, demonstrated that Nf1+/- 
macrophages had a two-fold increase in proliferation (Figure 28b) and migration 
(Figure 28c) compared to WT macrophages.  Further, Nf1+/- macrophages 
showed significantly increased adhesion on fibronectin compared to WT 
macrophages (Figure 28d).  Consistent with increased accumulation of Nf1+/- 
macrophages into the neointima in vivo, this data clearly demonstrates that 
heterozygous inactivation of Nf1 increases macrophage migration, proliferation 
and adhesion in vitro.  Collectively, this cellular and genetic data demonstrates 
that neointima formation in Nf1+/- mice is directly related to increased “vascular 





















Figure 28.  Effect of heterozygous inactivation of Nf1 in macrophages in 
vitro.  A)  Complete blood analysis of percent monocytes in circulation from 
peripheral blood from WT (open bars) and Nf1+/- mice (black bars).  Data 
represents the average percentage ± SEM, n=8, *p=0.02 for Nf1+/- vs. WT by 
Student’s unpaired t test.  B)  Proliferation of WT (open bars) and Nf1+/- (black 
bars) bone marrow derived macrophages in response to M-CSF stimulation.  
Data represents average CPM (thymidine counts per minute) ± SEM, n=4, 
*p<0.001 for WT macrophages 0 ng M-CSF vs. WT macrophages stimulated with 
30ng, 40ng and 50ng M-CSF and **p<0.001 for Nf1+/- macrophages stimulated 
with M-CSF vs. WT macrophages stimulated with M-CSF by one-way ANOVA 
with Tukey post-test.  C)  Haptotaxis of WT and Nf1+/- macrophages in response 
to 100ng M-CSF.  Data represents average number of migrated cells ± SEM, 
*p<0.001 for WT macrophages stimulated with 0ng M-CSF vs. WT macrophages 
stimulated with 100ng M-CSF, **p<0.001 for WT macrophages stimulated with 
0ng M-CSF vs. Nf1+/- macrophages stimulated with 0ng M-CSF and #p<0.001 for 
Nf1+/- macrophages stimulated with 0ng M-CSF vs. Nf1+/- macrophages 
stimulated with 100ng M-CSF by one-way ANOVA with Tukey post-test.  D)  
Adhesion of WT and Nf1+/- macrophages to fibronectin.  Data represents average 
optical density (600nm) ± SEM, n=4, *p<0.001 for WT macrophages vs. Nf1+/- 
macrophages and **p<0.01 for Nf1+/- macrophages at 60 min vs. Nf1+/- 
macrophages at 15 min, 30 min and 45 min by one-way ANOVA with Tukey post-




Nf1+/- Mice Do Not Have Evidence of Chronic Inflammation. 
 The increased macrophage function observed in vitro suggests that Nf1+/- 
mice may exhibit chronic inflammation due to the increased function of Nf1+/- 
macrophages.  To determine if Nf1+/- mice have evidence of chronic 
inflammation, we assayed for the presence of inflammatory cytokines and 
chemokines in plasma isolated from the peripheral blood of uninjured Nf1+/- mice 
and WT mice.  Analysis of plasma samples demonstrated that there was no 
difference in circulating levels of the cytokines IL-1β, IL-6, IL-10 and TNFα, or the 
chemokines M-CSF and MCP-1 between Nf1+/- mice and WT mice (Figure 29).  
This is not a surprising observation given that Nf1+/- mice do not develop vascular 
lesions in the absence of an external challenge.  Therefore, in order to determine 
the acute effects of carotid artery ligation in future studies, plasma samples need 
to be collected at early timepoints post-injury and assayed for increased levels of 
inflammatory cytokines.  Preliminary data suggests that carotid artery ligation 
may increase the levels of circulating Cd11+Gr-1+ monocytes in Nf1+/- mice above 
baseline at 24 hours post-ligation compared to WT mice (Figure 30).  However, 
in order to determine if there is a significant increase in circulating monocytes 
and increased levels of inflammatory cytokines and chemokines in Nf1+/- mice in 
response to injury, multiple studies need to be completed to analyze peripheral 
blood samples from injured mice at numerous timepoints.  Studies will be 
continued in Dr. Ingram’s lab to identify whether carotid artery ligation results in 
acute systemic inflammation in Nf1+/- mice by assaying for increased 
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inflammatory cytokines production as well as dissecting the role of Nf1+/- 







































Figure 29.  Analysis of circulating inflammatory cytokines and chemokines 
in Nf1+/- and WT mice.  Circulating levels of cytokines and chemokines in 
plasma samples isolated from uninjured WT (open bars) and Nf1+/- (black bars) 


































Figure 30.  Flow cytometric analysis of circulating monocytes 24 hours 
post-ligation.  Peripheral blood analysis of circulating Cd11b+Gr-1+ monocytes 
in WT (left panel) and Nf1+/- (right panel) mice 24 hours post-ligation.  Black box 






















NF1 Patients Have Evidence of Chronic Inflammation   
Given the observation of vascular inflammation in Nf1+/- mice in vivo in 
response to injury, we tested whether NF1 patients had cellular and cytokine 
evidence of vascular inflammation by assaying for previously established 
biomarkers linked to human vasoocclusive disease.  Utilizing mulitparameter flow 
cytometry, we analyzed mononuclear cells isolated from the peripheral blood of 
NF1 patients and age and sex-matched healthy controls for inflammatory 
monocyte populations.  The frequency of total circulating monocytes was initially 
determined by assaying total mononuclear cells for monocytes that co-expressed 
the cell surface antigens, CD45 and CD14 (185).  NF1 patients had significantly 
increased frequencies of circulating monocytes compared with healthy controls 
(Figure 31a).  We further measured specific circulating monocyte populations to 
identify pro-inflammatory monocytes, which co-express CD14 and CD16 
(CD14+CD16+) (186).  Pro-inflammatory monocytes have been identified in the 
peripheral blood of patients with coronary artery disease and atherosclerosis 
(102, 107) and have been shown to produce more inflammatory cytokines 
compared to classical monocytes (146, 186).  Analysis of NF1 patient peripheral 
blood monocytes identified a population of monocytes that had increased CD16 
expression (CD14dimCD16bright) compared to the traditional CD14+CD16+ 
population, a population that was not observed in peripheral blood samples from 
healthy controls (Figure 31b).  Based on a side scatter profile, the population of 
CD14dimCD16bright monocytes is larger in size compared with other monocyte 
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populations, indicating the cells have increased granularity, a characteristic of 





































Figure 31.  Identification of circulating monocytes from peripheral blood of 
healthy adult controls and NF1 patients.  A)  Representative PFC analysis of 
peripheral blood monocytes by CD14 and CD16 cell surface expression in 
healthy adult controls (left panel) and NF1 patients (right panel).  Black box 
identifies CD14dimCD16bright monocyte population.  Data represents 5 
independent observations.  B)  Quantification of the frequency of CD45+CD14+ 
monocytes in circulation from healthy adult control and NF1 patient peripheral 
blood MNCs.  Data represents the mean frequency ± SEM, n=5, *p=0.024 by 
Student's unpaired t test with Welch correction.  C)  Quantification of the 
frequency of CD45+CD14dimCD16bright monocytes in circulation from healthy adult 
control and NF1 patient peripheral blood MNCs.  Data represents the mean 














Pro-inflammatory monocytes produce a numerous inflammatory cytokines 
and chemokines that have been implicated in neointima formation.  Therefore, 
based on the increased levels of circulating monocytes and the presence of an 
activated monocyte population, we hypothesized that NF1 patients would also 
have increased levels of inflammatory cytokines and chemokines in their 
peripheral blood, a correlation that has been made in other patient populations 
with the progression of vascular disease (100, 103, 188, 189).  We analyzed 
plasma samples from NF1 patients and healthy controls for the presence of the 
specific pro-inflammatory cytokines IL-1β, IL-6, interferon-γ (IFN-γ) and TNFα.  
Analysis of plasma samples from NF1 patients with no known vascular disease 
(17±2 years, n=6) and healthy controls (18.5±3.4 years, n=7) showed a trend 
toward increased levels of IFN-γ (p=0.4399) and TNFα (p=0.17) as well as the 
growth factor GM-CSF (p=0.4228) but were not significant with the limited 
sample set (Figure 32).  Further, the plasma samples showed no difference in 
levels of the chemoattractant protein MCP-1 between control and NF1 patient 
samples (Figure 32).  However, significantly elevated levels of IL-1β and IL-6 
were observed in the plasma samples from NF1 patients compared to controls 
(Figure 33).  The production of pro-inflammatory cytokines has been linked to the 
activation of the endothelium and increased expression of chemokines involved 
in the recruitment of monocytes to the vessel wall (112, 143, 144, 151, 190).  
Interestingly, NF1 patient plasma samples had significantly elevated levels of 
soluble fractalkine (Figure 33), an adhesion molecule expressed on inflamed 
endothelium, which is involved in rapid, high-affinity binding of monocytes (151, 
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191, 192).  The increased number of circulating monocytes and production of 
inflammatory cytokines provides direct evidence of chronic inflammation in NF1 
and elevation of biomarkers previously identified as critical risk factors in other 



































Figure 32.  Analysis of inflammatory cytokines and chemokines from NF1 
patient and healthy control plasma.  Determination of cytokine levels in 
plasma isolated from control peripheral blood and NF1 patient peripheral blood.  
A) IFN-γ levels in pg/mL from control and NF1 patient plasma samples.  Data 
represents the average pg/mL ± SEM, n=6.  B)  TNFα levels in pg/mL from 
control and NF1 patient plasma samples.  Data represents the average pg/mL ± 
SEM, n=6.  C)  GM-CSF levels in pg/mL from control and NF1 plasma samples.  
Data represents the average pg/mL ± SEM, n=6.  D)  MCP-1 levels in pg/mL 
from control and NF1 plasma samples.  Data represents the average pg/mL ± 
































Figure 33.  Analysis of inflammatory cytokines and chemokines from NF1 
patient and healthy control plasma.  Determination of cytokine levels in 
plasma isolated from control peripheral blood and NF1 patient peripheral blood.  
A)  IL-1β levels in pg/mL.  Data represents the average pg/mL ± SEM, n=6, 
*p=0.014 by Mann-Whitney test.  B)  IL-6 levels in pg/mL.  Data represents the 
average pg/mL ± SEM, n=6, *p=0.046 by Student's unpaired t test of log 
transformed data.  C)  Fractalkine levels in pg/mL.  Data represents the average 




















NF1 is an autosomal dominant genetic disorder with a wide range of both 
malignant and non-malignant clinical manifestations.  In contrast to some NF1 
cancers where loss of heterozygosity at the NF1 allele is a prerequisite for tumor 
development, many of the non-malignant complications of NF1, including 
learning disorders, skeletal abnormalities and vascular disease occur secondary 
to aberrant NF1+/- cellular functions within a specific tissue microenvironment (21, 
37, 38, 50, 126).  Thus, study of the effects of NF1 haploinsufficiency in different 
cell lineages is imperative for understanding the diverse morbidities associated 
with NF1.  Vasculopathy associated with NF1 is an under-recognized 
complication of the disease and contributes to significant premature morbidity 
and mortality in patients.  NF1 vasculopathy was first described in 1945 (21).  
Since the original report, multiple clinical studies demonstrate that different 
locations within the entire arterial tree may be affected in NF1 patients (15, 20).  
An important tool for understanding the pathogenesis of NF1 vasculopathy is the 
development of in vivo animal models, which accurately recapitulate some, if not 
all, aspects of the clinical disease. 
An emerging paradigm in vascular biology is that neointima formation in 
response to injury is tightly controlled by the Ras-Mek-Erk signaling axis in 
resident cells within the vascular wall including endothelial cells and VSMCs (66, 
68-71, 171).  Specifically, prior animal studies indicate that increased Ras 
activation augments VSMC proliferation and migration, and the subsequent 
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development of vascular lesions (63, 65, 68, 72).  These vascular lesions are 
characterized by intimal wall hyperplasia and neointima formation, which 
ultimately leads to occlusive vascular disease.  In support of the importance of 
Ras in occlusive vascular disease, adenoviral mediated transfer of a dominant 
negative H-Ras into VSMCs prevents the development of stenotic lesions in rats 
after mechanical arterial injury by inhibiting the proliferation and migration of 
VSMCs (68).  Similar results were obtained when animals were treated with a 
chemical Ras farnesyltransferase inhibitor prior to arterial mechanical injury (69). 
Finally, when genetically engineered mice harboring constitutively active 
PDGF-βR only in VSMCs were intercrossed with low density lipoprotein receptor 
knockout mice, which have a predisposition to developing atherosclerosis, the 
mutant progeny developed aneurysms and a marked susceptibility to 
atherosclerosis (63).  The mutant mice also showed hyperproliferation of VSMCs 
and increased Erk activation in vivo (63).  Consistent with the central pathogenic 
role of hyperactivation of the PDGF-βR-Ras-Erk signaling pathway in controlling 
VSMC proliferation in vivo, mutant mice treated with imatinib mesylate, an 
inhibitor of PDGF-βR signaling, did not develop atherosclerosis or aneurysms 
(63).  Collectively, these studies provide a paradigm where hyperactivation of 
Ras and the PDGF-βR signaling pathway activates a discrete set of biochemical 
effectors which potentiates VSMC proliferation and migration in vivo.  
Recent genetic and biochemical studies from Dr. Ingram's laboratory 
demonstrated that neurofibromin functions as a formal Ras GAP in both murine 
and human VSMCs in vitro (48).  Specifically Nf1+/- VSMCs have increased 
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migration and proliferation in response to PDGF-BB stimulation via 
hyperactivation of the Ras-Erk signaling pathway (48).  Given the importance of 
PDGF-βR-Ras-Erk signaling in vascular lesion formation in vivo and the 
observation that Nf1+/- VSMCs have increased proliferation and migration in vitro 
in response to PDGF-BB, we utilized a well-established model of arterial injury to 
develop an in vivo model of NF1 vasculopathy. 
 
Development of an in vivo model of NF1 vasculopathy. 
In order to develop a model that properly reflected human disease, we 
utilized Nf1+/- mice, which are genetically similar to NF1 patients.  To date, loss of 
heterozygosity has not been described in the vascular cells of NF1 patients and 
therefore haploinsufficiency of Nf1 was appropriate for this model.  Nf1+/- mice do 
not develop vascular lesions in the absence of an external challenge.  In order to 
induce vascular lesion formation, we utilized a carotid artery injury model which 
mimics arterial microinjury by denuding the endothelium (157).  Loss of the 
endothelium, exposes the underlying matrix and collagen to the circulation, 
initiating a wound healing response.  Initially, platelets are recruited to the 
exposed collagen followed by leukocyte recruitment (111, 157).  Platelets are a 
potent source of PDGF (158, 159), which has been reported to be necessary to 
stimulate the migration of quiescent medial VSMCs into the intima area of the 
vessel (61, 62, 160).  The migration and proliferation of VSMCs in the intima area 
continues until reendothelialization of the lumen has occurred.   
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Utilizing C57Bl/6 male mice, we demonstrated that Nf1+/- mice had 
enhanced neointima formation in response to carotid artery injury compared to 
WT mice (Figure 8).  Specifically, Nf1+/- mice had a five-fold increase in neointima 
area compared to WT mice which resulted in approximately 35% lumen stenosis 
(Figure 8).  Morphologically, the neointima of Nf1+/- mice was reminiscent of 
vascular lesions described in NF1 patients.  Immunohistochemistry was used to 
determine the cellular content of the neointima and anti-α-SMA staining 
demonstrated that greater than 75% of the cells within the neointima of Nf1+/- 
mice were VSMCs, consistent with clinical reports from NF1 patients.  Further, 
immunohistochemistry demonstrated that Nf1+/- mice had significantly increased 
cellular proliferation within the neointima 21 days post vascular injury compared 
to WT mice (Figure 11).  Proliferation of VSMCs, a function known to be 
regulated in vitro by Ras-Erk signaling (48), suggests that arterial injury results in 
Ras activation in Nf1+/- mice.  Using phospho-Erk as a marker of Ras activation, 
we determined that vascular injury results in hyperactivation of the Ras-Erk 
signaling axis in Nf1+/- mice, resulting in enhanced neointima formation (Figure 
12).  Consistent with our prior in vitro observations, we now provide data in the 
present study to demonstrate that haploinsufficiency at Nf1 in vascular wall 
resident cells leads to hyperactivation of Erk, increased VSMC proliferation, and 
formation of an enlarged neointima in vivo in response to injury.  This observation 
is consistent with the concept that precise regulation of the Ras-Erk signaling 




Pharmacological Inhibition of Neointima Formation in Nf1+/- Mice. 
Imatinib mesylate is a potent inhibitor of both PDGF-βR-Ras-Erk signaling 
and C-kit receptor activation in vivo (195) and prevents neointima formation in 
other mouse models after arterial injury (63, 115).  Based on these prior studies 
and the fact that Nf1+/- VSMCs are hypersensitive to PDGF-BB stimulation in 
vitro, we tested whether imatinib mesylate could prevent or delay neointima 
formation in Nf1+/- mice after vessel injury.  In Figure 14, we demonstrated that 
treatment of Nf1+/- mice with imatinib mesylate completely abrogates neointima 
formation in response to injury.  The inhibition of neointima formation is 
accompanied by an inhibition of cell proliferation and Ras-Erk activation (Figure 
15).  In this model, mice were treated with imatinib mesylate daily for 10 days as 
previously described (115), beginning three days prior to injury to ensure a 
therapeutic, steady-state level of imatinib mesylate in circulation on the day of 
injury.  The mice continued recovering from day 7 through day 21 with no 
imatinib mesylate administration.  These observations indicate that the events 
necessary for neointima formation in Nf1+/- mice occur within the first week after 
injury and are a result of either PDGF-βR or C-kit activation.   
While we do detect inhibition of Erk activation and proliferation in VSMCs 
in the vessel wall with imatinib mesylate treatment in vivo, it is possible that 
imatinib mesylate also prevents the influx of BMDCs to the evolving neointima in 
Nf1+/- mice to account for the observed treatment effect.  In support of this 
concept, recent murine genetic studies demonstrate that activation of the C-kit 
receptor in BMDCs mobilizes either VSMCs or cells that express VSMC antigens 
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to enhance the progression of an evolving neointima by either direct cellular 
integration or paracrine stimulation of resident cells in the vessel wall (115, 196).  
This observation is especially intriguing since previous studies from our group 
demonstrate that Nf1+/- bone marrow derived cells have increased proliferation, 
migration, and survival in response to Kit ligand stimulation both in vitro and in 
vivo(125-127).             
This model has established that arterial injury results in enhanced 
neointima formation in Nf1+/- mice, characterized by increased accumulation of 
VSMCs and hyperactive Ras-Erk signaling compared to WT mice.  These 
observations are important since they recapitulate the phenotype of NF1 patients 
and are consistent with in vitro reports of hyperactive neurofibromin deficient 
VSMCs.  While these studies establish that Nf1 haploinsufficiency is sufficient to 
predispose mice to an enlarged neointima compared to WT controls in vivo, 
several questions remain.  Blood vessels are composed primarily of a continuous 
monolayer of ECs surrounded by VSMCs.  Dysfunction of either cell type can 
result in intimal hyperplasia, which can ultimately lead to occlusive vascular 
disease.  Further, animal studies of arterial mechanical injury have now shown 
that mobilization and transmigration of BMDCs into the intima in response to 
vascular injury directly contributes to neointima formation (111, 115-117, 196).  
Therefore, based on the complex interaction between cells in response to arterial 
injury and the global control of Ras signaling, it is essential that the predominant 
cell lineage(s) involved in neointima formation in Nf1+/- mice be dissected in order 
to determine the optimal treatment and prevention of NF1 vasculopathy.   
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Dissecting the Cellular Contribution to NF1 Vasculopathy. 
Vessel wall homeostasis requires a tightly regulated interaction between 
vascular cells and circulating BMDCs.  The endothelium functions as a barrier 
between the VSMCs within the vessel wall and the blood, controlling the 
transmigration of circulating cells into the vessel and inhibiting the proliferation 
and migration of VSMCs within the vessel wall (56, 57).  Endothelial dysfunction 
can be caused by a number of factors including oxidative stress, inflammatory 
cytokine activation, changes in shear stress or injury (113, 197-200).  A hallmark 
of endothelial dysfunction is the reduced production of nitric oxide, a potent 
inhibitor of VSMC proliferation (201).  Further, endothelial activation by 
inflammatory cytokines or changes in shear stress upregulates the expression of 
adhesion molecules on the surface of the endothelium, recruiting circulating 
inflammatory cells to the vessel wall (56, 112, 113, 202, 203).  Endothelial 
activation is one of the first steps in vascular inflammation, initiating a cascade of 
events that, if unchecked, result in vascular lesion formation (105, 204).  
Neurofibromin is a known critical regulator of Ras activation in ECs, VSMCs and 
BMDCs, however it remains unclear whether endothelial dysfunction, 
hyperproliferation or migration of VSMCs or increased activation of circulating 
BMDCs is the predominant factor in neointima formation in Nf1+/- mice.  
Therefore, we interrogated the role of heterozygous inactivation of Nf1 in ECs, 
VSMCs and BMDCs to neointima formation. 
In this study, we demonstrated that heterozygous inactivation of Nf1 in 
ECs or VSMCs alone was insufficient to recapitulate the enhanced neointima 
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formation observed in Nf1+/- mice in response to carotid ligation.  Carotid ligation 
was chosen for inducing neointima formation in these studies because of the 
techniques reproducibility.  Neointima formation in response to carotid ligation 
results from changes in shear stress and the migration of leukocytes into the 
vessel wall (108, 161).  In our studies, morphometric analysis showed that WT, 
Nf1flox/+;Tie2cre and Nf1flox/+;SM22cre had similar neointima formation in 
response to ligation, and all were significantly lower than Nf1+/- mice (Figure 17 
and 18).  However, heterozygous inactivation of Nf1 in BMDCs alone was 
sufficient for neointima formation in response to vascular injury (Figure 19 and 
20).  Specifically, we showed that both WT and Nf1+/- mice reconstituted with 
Nf1+/- BMDCs had enhanced neointima formation characterized by an 
accumulation of BMDCs in response to carotid ligation (Figure 18 and 19).  At 28 
days post-ligation, mice transplanted with WT bone marrow had minimal 
neointima formation, suggesting that heterozygous inactivation of Nf1 results in 
increased recruitment and accumulation of BMDCs.  Specifically, 
immunohistochemistry demonstrated that in WT and Nf1+/- mice reconstituted 
with Nf1+/- BM, 25-30% of the cells within the neointima were bone marrow 
derived determined by GFP expression (Figure 23).  The presence of Nf1+/- 
BMDCs within the neointima at 28 days post-ligation suggests inflammation is a 
predominant factor in neointima formation given that in the original report of 
carotid artery ligation, Kumar et al. described that at 28 days post-ligation, 
inflammatory cells were not present in the neointima of WT mice and the majority 
of the cells were VSMCs (161).   
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The attachment and transmigration of BMDCs has been reported by 
others to be essential for neointima formation (108, 110, 111).  BMDCs 
contribute to neointima formation through the production of cytokines and growth 
factors to stimulate VSMC growth and proliferation as well as the addition of 
cellular mass to the neointima (108, 111, 150, 205, 206).  It has previously been 
reported that BMDCs transmigrate into the neointima in response to arterial injury 
and differentiate into α-SMA positive VSMCs (118).  To determine the origin of 
VSMCs within the neointima of both WT and Nf1+/- mice reconstituted with either 
WT or Nf1+/- BMDCs, arterial cross-sections were co-stained with an anti-GFP 
antibody, to identify BMDCs, and an anti-α-SMA antibody, to identify VSMCs.  
Analysis of co-stained arterial cross-sections under high-powered magnification 
determined that anti-GFP positive cells and anti-α-SMA positive cells did not 
colocalize (Figure 23), indicating that the VSMCs within the neointima and vessel 
wall were locally derived and not bone marrow derived VSMCs.  These results 
are consistent with other reports utilizing adoptive hematopoietic stem cell 
transfer in models of vascular lesion formation (207).  In order to fully understand 
the mechanism of neointima formation it is essential to determine the lineage of 
the BMDCs within the neointima in response to arterial injury.      
Therefore, we analyzed arterial cross-sections from WT and Nf1+/- mice 
transplanted with either WT or Nf1+/- BMDCs utilizing immunohistochemistry to 
identify the lineage(s) of BMDCs within the neointima.  Anti-CD45 staining of 
arterial cross-sections showed the same staining pattern as anti-GFP staining, 
indicating that the BMDCs within the neointima were of myeloid origin (Figure 
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25).  Leukocytes, specifically lymphocytes and monocytes, have been shown to 
contribute to neointima formation in response to injury.  Staining of arterial cross-
sections to identify lymphocytes, CD3 positive cells, showed that lymphocytes did 
significantly accumulate within the neointima and 28 days post arterial ligation 
(Figure 26).  Studies of lymphocyte infiltration in response to endothelial 
denudation have shown that lymphocytes are present at the vessel wall as early 
as 1 hour post-injury (172).  Further, in vivo studies using lymphocyte deficient 
mice demonstrate that the infiltration of lymphocytes in response to injury have a 
protective effect, inhibiting the proliferation of VSMCs (172).  Therefore, the role 
of lymphocytes in neointima formation in Nf1+/- mice cannot be discarded without 
determining if there are differences in lymphocyte infiltration at earlier timepoints 
in response to arterial injury compared to WT mice.  Assaying for the presence of 
macrophages, using anti-Mac3 immunohistochemistry, demonstrated that greater 
than 85% of the Nf1+/- BMDCs within the neointima were macrophages (Figure 
27).  Mac3 is a glycoprotein that is produced and expressed by macrophages, 
but not lymphocytes or monocytes (208).  Therefore, if there are immature 
macrophages within the vessel wall, they will not be identified by anti-Mac3 
staining, which could account for the 10-15% of GFP positive cells that are not 
CD3 or Mac3 positive.  These studies identify Nf1+/- BMDCs as necessary and 
sufficient for neointima formation and determine a new role for neurofibromin as 
an important regulator of macrophage function in vivo and in vitro.  Further, this 
data provides a novel paradigm of "vascular inflammation" as the major 
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determinant of vessel occlusion despite the role of neurofibromin in regulating EC 
and VSMC function.  
 
The Role of Macrophages in Neointima Formation. 
The accumulation of macrophages in the vessel wall in response to 
arterial injury suggests that inflammation has a direct contribution to neointima 
formation in Nf1+/- mice.  Macrophages play an important role in neointima 
formation through the production of growth factors and cytokines that activate 
ECs and stimulate VSMC migration and proliferation (209-211).  Further, 
macrophages are a source of matrix proteases, which cleave collagen within the 
vessel wall (212, 213) and activation of matrix metalloproteinases, specifically the 
gelatinases MMP-2 and MMP-9, breaks down collagen within the vessel wall 
allowing VSMCs to migrate from the media into the intima in response to 
chemotactic agents generated by arterial injury (137, 214, 215).  MMPs are 
expressed by macrophages and VSMCs and their expression can be induced by 
a number of cytokines and growth factors, including TNFα, IL-1β and PDGF-BB 
(138, 140, 141).  MMP-9 expression has been shown to be induced in response 
to arterial injury and genetic deletion significantly impaired VSMC migration in 
vitro and in vivo (216).  The expression and activation of the MMPs has not been 
described in neurofibromin deficient VSMCs or macrophages, however based on 
in vitro data that demonstrates that Nf1+/- VSMCs are hyperresponsive to PDGF-
BB and our in vivo observations of increased macrophage function, we 
hypothesize that arterial injury in Nf1+/- mice would enhance MMP activation, 
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contributing to neointima formation.  Along with cellular migration and 
proliferation, matrix remodeling significantly contributes to neointima formation.  It 
has previously been reported that cellular proliferation is drastically reduced after 
2 weeks post-injury although the neointima continues to develop due to the 
accumulation and remodeling of matrix (161, 217).  The continued growth of the 
neointima in the absence of VSMC proliferation suggests a mechanism by which 
the WT mice transplanted with Nf1+/- bone marrow had equivalent neointima 
formation to Nf1+/- mice transplanted with Nf1+/- bone marrow 28 days post-injury 
(Figure 21 and 22) despite the observation that Nf1+/- mice had significantly more 
BMDCs within the neointima (Figure 23).  These observations suggest that Nf1+/- 
vascular cells secrete increased levels of chemokines, which results in increased 
recruitment, retention or survival of BMDCs in the neointima compared to WT 
vascular cells.  We predict that Nf1+/- mice reconstituted with Nf1+/- bone marrow 
will have increased neointima formation compared to WT mice with Nf1+/- bone 
marrow at earlier time points (i.e. 1-2 weeks) due to the increased accumulation 
of BMDCs in response to injury.        
In order to fully understand the role of Nf1+/- macrophages in neointima 
formation, functional studies need to be completed.  There are multiple 
mechanisms that could account for increased accumulation of Nf1+/- 
macrophages in the evolving neointima including: 1) increased recruitment to the 
site of injury, 2) increased proliferation within the neointima, 3) increased 
retention in the neointima or 4) increased survival.  Recent in vitro studies 
completed in Dr. Kapur’s lab indicate that bone marrow derived Nf1+/-  
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macrophages have increased migration and proliferation in response to M-CSF 
stimulation (Figure 28).  M-CSF is a pro-inflammatory cytokine that regulates 
macrophage function and is upregulated in vivo in response to arterial injury(211, 
218).  Further, exogenous administration of M-CSF significantly enhanced 
neointima formation through the increased recruitment of BMDCs to the site of 
injury(211).  These observations suggest that Nf1+/- bone marrow derived 
macrophages may have increased recruitment to the site of arterial injury in 
response to M-CSF production.  Further, once emigrated into the emerging 
neointima, Nf1+/- macrophages may have increased proliferation in response to 
M-CSF and other growth factors produced in response to injury, furthering the 
accumulation of BMDCs within the neointima.  However, it is not known whether 
Nf1+/- vascular cells produce increased levels of M-CSF or other chemokines (i.e. 
MCP-1) in response to arterial injury that are involved in monocyte recruitment.  
Functional in vitro studies need to be completed to determine if heterozygous 
inactivation of Nf1 in VSMCs promotes the migration and proliferation of 
macrophages.  Along with increased recruitment and proliferation, M-CSF 
stimulation has also been shown to promote the survival of monocytes and 
macrophages.      
Increased survival of Nf1+/- macrophages within the neointima would 
enhance neointima formation through prolonged production of growth factors and 
matrix remodeling.  In addition to M-CSF, the multifunctional protein osteopontin 
(OPN) has also been shown to promote the survival of macrophages by inhibiting 
apoptosis (219).  In vivo, OPN is upregulated in response to arterial injury (220-
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222) and overexpression of OPN results in increased medial thickening and 
neointima formation (223), while genetic ablation of OPN results in protection 
against aneurysm formation (224).  In a recent report on bone malformation and 
NF1, Li et al. (225) demonstrated that Nf1+/- mice have increased serum levels of 
OPN compared with WT controls.  Given the multiple effects of OPN, this is an 
important finding.  In addition to its anti-apoptotic effects, OPN also stimulates 
VSMC proliferation and migration (226) and activates MMP-2 and MMP-9 
activity, suggesting a role of OPN in vascular lesion formation in Nf1+/- mice.  
While these observations suggest potential mechanisms, further characterization 
of neointima formation in Nf1+/- mice needs to be completed in order to identify 
initiating factors.  Specifically, in vitro studies of Nf1+/- ECs, VSMCs and 
macrophages need to be completed to determine the role of neurofibromin in the 
production of cytokines and growth factors involved in neointima formation.  
Further, the expression and activity of MMPs needs to be characterized in Nf1+/- 
VSMCs and macrophages.  Information gathered from these studies can be 
applied to the expandable in vivo model that was developed in this study.  
Utilizing cre/lox technology and immunohistochemistry the direct role of cytokines 
and growth factors at early timepoints in neointima formation can be dissected.      
  
Evidence of Vascular Inflammation in NF1 Patients. 
The direct role of Nf1+/- BMDCs and the accumulation of macrophages 
within the neointima of mice reconstituted with Nf1+/- bone marrow suggests that 
vascular inflammation contributes to neointima formation.  This observation is 
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intriguing given that inflammation is linked to vascular disease in patient 
populations including atherosclerosis and coronary artery disease (107, 227-
229).  In vascular inflammation, increased expression of adhesion molecules by 
the endothelium and the production of chemokines lead to a recruitment of 
BMDCs, specifically monocytes, to the site of injury initiating an inflammatory 
response (112, 143, 144, 151, 190).  In this study, we determined that NF1 
patients, with no overt vascular disease, have increased numbers of circulating 
monocytes compared to healthy controls (Figure 31).  Further, we identified a 
population of monocytes in NF1 patients that has characteristics of an activated 
state, including increased CD16 expression and increased size (187).  Increased 
levels of the pro-inflammatory cytokines IL-1β and IL-6 in plasma samples from 
NF1 patients (Figure 33) supports our observation that NF1 patients have 
increased activated monocytes in circulation given that, in peripheral blood, 
monocytes are the main producers of IL-1β and IL-6 (230, 231).  IL-1β 
stimulation of ECs increases the production of inflammatory cytokines, including 
IL-1β and IL-6 as well as the production of chemokines which recruit monocytes 
to the vessel wall, amplifying the inflammatory response (231, 232).  IL-1β has 
also been shown to induce the production of IL-6 in VSMCs (233).  In vitro 
studies have indicated that IL-6 stimulation of VSMCs results in increased 
proliferation through the production of PDGF (234, 235).  These observations 
identify a mechanism by which increased circulating monocytes and increased 
levels of inflammatory cytokines predispose NF1 patients to vasculopathy given 
that neurofibromin deficient VSMCs are hyperproliferative in response to PDGF.   
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Along with endothelial activation, cytokines have been described to affect 
arterial endothelial dependent vasodilation.  Iversen et al. demonstrated that the 
cytokines TNFα, IL-6 and IL-10 induced arterial contraction in an endothelial 
dependent manner (236).  In studies completed by our collaborator, Dr. Jan 
Friedman, NF1 patients showed decreased endothelial dependent dilation 
compared to normal standards with no difference detected in smooth muscle 
dependent dilation.  An important observation to this study was that reduced 
endothelial dependent dilation was observed in patients with no known vascular 
disease.  In our study, we tested endothelial dependent vasodilation and 
analyzed plasma samples of NF1 patients (17±2 years of age) with no known 
vascular disease and showed that our patient population did not have impaired 
endothelial dependent vasodilation but did have increased levels of the pro-
inflammatory cytokines IL-1β and IL-6.  Based on these observations, 
inflammation precedes endothelial dysfunction in NF1 patients.  Chronic 
inflammation results in endothelial dysfunction through the stimulation of the 
endothelium to produce adhesion molecules and chemokines that attract 
monocytes to the vessel wall.  The attachment of monocytes to the vessel wall 
further exacerbates endothelial dysfunction through the production of activating 
cytokines and reactive oxygen species, which result in premature senescence.  
Therefore, the findings of this study suggest that all NF1 patients may have sub-
clinical vascular disease.  We are currently conducting studies to determine the 
incidence of subclinical vascular disease in NF1 patients along with identifying 
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potential biomarkers that correlate to the progression of vascular disease in 
patients.      
In addition to increased levels of inflammatory cytokines, we identified that 
NF1 patients have increased levels the potent chemokine and adhesion molecule 
fractalkine (Figure 33).  Membrane-bound fractalkine is an adhesion molecule 
expressed on an inflamed endothelium when activated by pro-inflammatory 
cytokines, such as TNFα and IL-1β (143, 152).  Fractalkine produces a high-
affinity interaction with CX3CR1 expressing cells, including inflammatory 
monocytes, which allows cells to rapidly bind to the endothelium under normal 
flow conditions (151, 191, 192).  Fractalkine is cleaved from the cell membrane, 
resulting in soluble fractalkine which functions as a potent chemoattractant for 
monocytes (143).  CD14+CD16+ monocytes preferentially express CX3CR1 and 
their interaction with fractalkine induces the expression of IL-6 and MMP-9 in 
vitro, further perpetuating the inflammatory response and subsequent neointima 
formation (153, 154, 237).  In vivo, arterial injury upregulates the expression of 
fractalkine and genetic ablation of CX3CR1 abrogates neointima formation 
through impaired monocyte recruitment (155).  Further, single nucleotide 
polymorphisms within CX3CR1 have been described in humans with a reduced 
incidence of atherosclerosis and cardiovascular disease (238-240).  Taken 
together, upregulation of fractalkine expression in NF1 patients in response to 
increased inflammatory cytokines would result in increased recruitment and 
attachment of monocytes to the vessel wall leading to endothelial dysfunction 
and subsequent vascular disease.   
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In this study, we have developed an in vivo model of NF1 vasculopathy.  
We have demonstrated that Nf1+/- mice have increased neointima formation in 
response to injury and that the neointima is composed primarily of VSMCs, 
reminiscent of the patient phenotype.  Further, we identified hyperactive Ras 
signaling through either the PDGF-βR or C-kit activation as potential 
mechanisms for increased neointima formation.  The use of cre/lox technology 
and adoptive hematopoietic stem cell transfer techniques allowed us to 
interrogate the individual contribution of Nf1+/- ECs, VSMCs and BMDCs to 
neointima formation.  The studies reported here demonstrated that heterozygous 
inactivation of Nf1 in BMDCs alone is necessary and sufficient for neointima 
formation in response to arterial injury.  The neointima of mice reconstituted with 
Nf1+/- bone marrow was characterized by an accumulation of macrophages, while 
mice transplanted with WT bone marrow showed minimal neointima formation.  
These observations demonstrate that neurofibromin is a critical regulator of 
macrophage function and that vascular inflammation is a leading factor in 
neointima formation.  Further, the increased levels of circulating monocytes and 
increased expression of inflammatory cytokines observed in NF1 patients provide 
evidence of chronic inflammation associated with NF1.  In sum, these studies 
provide the first genetic and cellular evidence of vascular inflammation in Nf1+/- 
mice and NF1 patients, and provide a framework for understanding the 
pathogenesis of NF1 vasculopathy and potential therapeutic and diagnostic 
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